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Abstract
Natural products experience an increasing importance in pharmaceutical re-
search where the development of new lead compounds, especially those with
antibiotic activity, has become imperative. The innovation gap left behind
by the termination of natural product research in most pharmaceutical com-
panies in the 1990s cannot be ﬁlled by chemically synthesized molecules,
contrary to the belief of the past decades. In order to reinvigorate natural
product development, the potential of so far neglected secondary metabo-
lite producers like gliding bacteria from the order of Myxococcales and the
genus Chitinophaga needs to be investigated more thoroughly. This thesis
comprises three projects dealing with the development and optimization of
fermentation processes for the production of secondary metabolites with an-
tibiotic activity from these gliding bacteria with the aim of increasing their
accessibility for further research.
The ﬁrst project covers the production of the anti-MRSA compound family
of elansolids by its native producer Chitinophaga sancti Fx7914. The focus
was set on the production of elansolid A2, the starting compound for semi-
synthetical medicinal chemistry approaches. The other important derivative
was elansolid C1, which is formed through nucleophilic addition of anthranilic
acid directly after biosynthesis. The production of elansolid C1 can thus serve
as a model process for precursor-directed biosynthesis with the ultimate goal
of facilitating structure-activity-relationship studies.
The other two projects deal with the process optimization of the heterolo-
gous production of two types of myxobacterial compound classes with the
model strain Myxococcus xanthus DK1622. The class of polyketides is repre-
sented by the α-pyrone myxopyronin A whereas the non-ribosomal peptide
synthetase-derived compounds are represented by the peptolide family of vio-
prolides. Process optimization was accomplished by improvement of the me-
dia composition and process parameters using statistical experiment design,
as well as precursor-feeding. These studies lead to the aim of investigating
M. xanthus as an expression platform for natural products in general.
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1 Theoretical Background
1.1 Natural Product Research Throughout History
1.1.1 Historical Use of Natural Products
Natural products (NPs) possessing pharmaceutical activity have ever since
been used by humans to treat illness. Archaeological evidence indicates that
medicinal plants were regularly used by people in prehistoric times. Some of
the earliest written records made by the ancient Egyptians (4,000 BC-395
AD) deal with this subject [1]. But the use was limited to substances
of plant, animal and mineral origin. Plant-based treatments were also
commonly administered in ancient Greece, 3,000 through 1,500 years ago.
The use of medicinal plants and remedies of animal and mineral origin is
documented for ancient cultures all over the world, like the Aztec and Maya
Indians and Chinese, Tibetan and Indian cultures. All these cultures share
the usage of selected molds, plant extracts or animal excretions to treat
infections [2, 3, 4].
The ﬁrst visualization of bacteria with the help of a microscope was
managed by Antoni van Leeuwenhoek in 1674 that enabled their scientiﬁc
exploration [5]. But for 200 years the idea that these microscopic organisms
produced substances that were pharmaceutically relevant to humans did
not occur to anyone. Early descriptions of the antagonistic actions of
various microorganisms and molds were made 1874 by William Roberts
and 1876 by John Tyndall [6]. In 1928, Alexander Fleming discovered
that an agar plate containing staphylococci had been contaminated by a
blue-green mold [7]. Around the mold was a halo of inhibited bacteria. He
reasoned that some substances excreted by the mold must have inhibited
the bacterial growth. The mold was later on identiﬁed as Penicillium
rubens whereupon the substance was subsequently called penicillin [8]. His
persistence and his belief in the idea made the diﬀerence to the scientists
which had made similar observations before [9]. It took 12 years for him to
get chemists interested in the extraction and puriﬁcation of the substance,
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which was ﬁnally published by an Oxford research group in 1940 [10]. Their
protocol eventually led to penicillin mass production and distribution in 1945.
1.1.2 The Golden Era of Antibiotics
The three decades beginning with the 1940s are now called the golden era
of antibiotics because in this time frame most of the antimicrobial sub-
stances still used today were discovered after the potential of microorgan-
isms and fungi as sources for human drugs had been realized. Among the
classes of antibiotics discovered in these era are the tetracyclines, macrolides,
cephalosporines, aminoglycosides, chloramphenicols and rifamycins, one ex-
ample of each is presented in Figure 1.1.
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Figure 1.1: Chemical structures of representatives of the antibiotic classes discovered in the golden
era of antibiotics. Pencillin G belongs to the class of β-lactams, erythromycin to the
class of macrolides, streptomycin to the class of aminoglycosides and ciproﬂoxacin to the
class of ﬂuoroquinolones.
The discovery of streptomycin from the actinobacterium Streptomyces griseus
in the 1940s prompted pharmaceutical companies to set up large research and
development programs for natural product discovery. They consisted mainly
of screening platforms for actinobacteria and fungi with activity against
pathogenic bacteria. These organisms were isolated from soil samples col-
lected all over the world. The testing for antibiotic activity was mainly
done by phenotypic screening against diﬀerent bacterial strains. This type of
screening is still applied today as described in more detail in chapter 1.6.1.
In the period from the 1940s to the 1970s, many of the important compounds
still used today were isolated from Streptomyces strains, e.g. the macrolides,
tetracyclines and aminoglycosides. With the exception of naladixic acid, an
3
NP-inspired synthetic derivative, all the antibacterial and antifungal drugs
discovered in this era were natural products. In the 1970s, the focus of the
screenings was broadened to anti-viral, anti-tumor and anti-parasitic activi-
ties as well as curative agents for non-infectious diseases [11, 12].
In the following years, the screening methodology stayed widely unchanged
but target-based screening approaches were launched as well. Unfortunately,
only a small number of natural products were discovered using this method,
whereas numerous second, third or fourth generation semi- or completely
synthetic derivatives of already known NPs were introduced to the mar-
ket. During the 1990s, platforms for combinatorial chemistry were devel-
oped which presented the opportunity for the synthesis of thousands of new
compounds. Advances in liquid handling technologies facilitated the high-
throughput screening (HTS) of these compounds. This led to the fact that
by the mid-1990s most pharmaceutical companies stopped screening natural
products.
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1.1.3 Natural Product Research Today
Despite the high contribution of natural products for the development of
drugs, the interest in NP-based drug discovery has decreased drastically with
the beginning of the 1980s. The reasons for this can be listed as the following
[12, 13, 14]:
• After the Convention of Biological Diversity treaty was signed in the
early 1990s, transfer and use of organisms from foreign countries has
been hindered.
• When screening a microorganism library, surreptitious hits of already
known compounds cannot be excluded.
• Natural products were seen as unﬁt for HTS screening because of non-
speciﬁc interferences due to ﬂuorescent or insoluble compounds in the
crude extracts.
• Natural products are in some cases only produced in small amounts by
the original producer, thus the availability of the substance is a problem.
• The high complexity of the molecules' structures results in chemical
synthesis with low yields, if at all possible.
• It was believed that combinatorial synthesis techniques would suﬃce to
provide new chemical lead structures.
The most promising way to overcome the faults of natural products was
thought to be the combinatorial chemistry approach. However, until 2014
there was only one drug approved by the Food and Drug Administration
(FDA) of the United States that is a formally a de novo synthetical chemi-
cal entity, namely the antitumor compound sorafenib (Nexavar) from Bayer
[15]. In general, 31 % of the therapeutic agents approved between 1981 and
2014 were synthetic products (synthesized without combinatorial chemistry)
whereas 46 % were natural products, derivatives thereof or NP-inspired syn-
thetic products (Figure 1.2A). These numbers emphasize the important role
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of natural products which to date cannot be met by synthetical molecules.
This is mainly due to the fact that NPs are natural metabolites which impli-
cates that they have general properties desirable for marketable drugs [16].
Thus, biologically relevant chemical space is better covered by natural prod-
ucts than by synthetic compounds as can be seen in Figure 1.2B.
Figure 1.2: A Composition of all 1562 new drugs approved from 1981-2014 based on their origin
(adapted from [17]). B The ZINC database harbors around 22 million commercially
available synthetic products available for screening. As a consequence, considerable
knowledge and eﬀort is necessary to ﬁnd biologically relevant compounds. In contrast,
all 160,000 natural products listed in the Dictionary of Natural Products are biologically
relevant of which 80 % are considered drug-like [13].
Consideration of the facts mentioned above led to an increase in natural
product research in the last years which is accompanied by new eﬀorts and
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methods to increase its output, some of which are reviewed as the following:
• The connection between taxonomy and metabolic proﬁle of an organ-
ism, known as chemotaxonomy, has come into focus in the past years.
Accordingly, new natural products can be identiﬁed through metabolic
proﬁling of an organism [18, 19].
• Fractionation of crude extracts to remove compounds that are likely to
cause artefacts. Together with advances in detection technologies, most
of the assays have become amenable to natural products [12].
• Using the One Strain - Many Compounds approach, the possibilities of
production of various compounds under diﬀerent cultivation conditions
by one single strain are explored [20].
• Most natural products isolated so far derive from soil-originating acti-
nobacteria or fungi (Table 1.2). The exploration of organisms from other
habitats, like marine or endophytic environments is thought to provide
promising sources for new chemical scaﬀolds [21].
Table 1.2: Approximate number of bioactive metabolites discovered in certain periods according to
the producer organism (adapted from [22]).
Species 1940-1974 1975-2000 2001-2010 Total
Actinobacteria 3400 7200 3100 13700
Streptomyces sp. 2900 5100 2400 10400
Other actinobacteria 500 2100 700 3300
Microscopic bacteria 800 2300 1100 4200
Myxobacteriales 25 400 210 635
Cyanobacteria 10 30 1250 1290
Fungi 1300 7700 6600 15600
• As more and more whole genome sequences become available, natural
product gene clusters can be explored in silico. Combinatorial biosyn-
thesis, namely the mixing and matching of biosynthetic units like polyke-
tide synthases (PKS), non-ribosomal peptide synthetases (NRPS) and
glycosyl transferases, further leads to the creation of novel metabolites
[13].
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• Many secondary metabolites are only produced in small quantities by
the original producer. Supply problems in the early stages of drug de-
velopment should be addressed by small-scale parallel fermentation ap-
proaches as well as better metabolic understanding of these organisms
[12].
1.2 Myxobacteria - A Proﬁcient Source of Natural Products
Natural products deriving from microorganisms have been to date the most
successful weapon against infectious diseases are a source for drug templates
approved for the treatment of cancer and other civilatory diseases. Partic-
ularly, members of the order of Actinomycetales have provided over 3,000
antibiotics of which over 90 % are produced by the genus Streptomyces alone
[23]. Most of the antibiotics on the market today, like streptomycin, chloram-
phenicol and tetracyclines are the original natural products or semisynthetic
derivates thereof, produced by diﬀerent Streptomyces species.
Another important contributor to antibiotic discovery has been the genus
Bacillus with the production of lanthionine-containing antibiotics (lantibi-
otics), gramicidin and bacteriocin [24, 25, 26]. Among the eubacteria, there is
a second group that produces a wide variety of chemical entities and over 450
antibiotics, called the myxobacteria [27]. Myxobacteria are δ-proteobacteria
that live mainly in the soil, preferentially in places rich with organic matter
and microbial life [28]. The order of Myxococcales consists of 55 species di-
vided in 28 genera [29]. Due to their nutritional requirements, myxobacteria
can be divided into two ecological groups that are also in agreement with
their phylogeny. Predators, like those of the genus Myxococcus, use other
bacteria or yeasts as food source. Cellulose decomposers, belonging mainly
to the genus Sorangium, decompose organic materials [30].
Although myxobacteria have been frequently found in the soil, some species
have also been isolated from a variety of environments all over the world
[31, 32, 33], including fresh water [34] and sea water [35], moors [36, 37],
anaerobic [38] and thermally extreme habitats [39, 40]. They exhibit a unique
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social behaviour (Fig. 1.3): although they grow independently, they move
by coordination of two diﬀerent motility forms, the A- and S-motility [41].
Using this gliding process, they form swarms to prey for nutrients. By se-
creting exoenzymes and antibiotics, they are able to degrade organic matter
or other bacteria and fungi [30, 42, 43]. If nutrients are scarce, the complex
life cycle of myxobacteria presents an advantage in surviving. Under starva-
tion conditions, the cells start to aggregate within the swarm, pile up and
produce fruiting bodies. The shape of these fruiting bodies can vary from
simple slime knobs containing myxospores in Myxococcus species to highly
sophisticated designs resembling trees with branching slime stalks formed
by Chondromyces robustus [28]. Within the fruiting bodies, vegetative cells
transform into myxospores, an environmentally resistant resting state, that
are ﬁrmly bound together. The myxospores can germinate and form a new
swarm when the environmental conditions have improved [44, 45].
This social behaviour of myxobacteria throughout their lifetime, accurately
related to as moving, killing, feeding and surviving together by Muñoz-
Dorado et al. [45] rises the question how the cooperation of single cells is
coordinated. Although the whole complexity of intercellular signalling has
not been resolved, a number of studies have shed light on this particular ﬁeld
of research. It is known that Myxococcus xanthus produces large quantities
of open membrane vesicles that contain hydrolytic enzymes and secondary
metabolites [47, 48]. This kind of intercell signalling was also discovered to
play a role in motility and fruiting body formation [49, 50]. The complexity
of multicellular behaviour may also account for the fact that myxobacte-
ria range among the prokaryotes with the largest genomes (13.0 Mb of So-
rangium cellulosum So ce 56 [51]). Around 8 % of the genome of Myxococcus
xanthus is dedicated to secondary metabolism. Because of their rich sec-
ondary metabolism, scientists eventually have discovered the myxobacteria
as a proﬁcient source for natural products particularly valuable as antibiotics,
antifungals and cytotoxic agents.
The ﬁrst account of antibacterial activity by a strain of Myxococcus virescens
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Figure 1.3: Life cycle of Myxococcus xanthus. When nutrients are present, cells divide and move
in a swarm to ﬁnd new resources. Upon starvation, cells aggregate to form mounds
and macroscopic fruiting bodies that harbour the myxospores. When nutrients become
available again, the spores germinate and complete the life cycle [46].
was described 1947 by Oxford [52]. The ﬁrst isolation of a myxobacterial sec-
ondary metabolite, ambruticin, was reported in 1977 [53]. Since then, com-
pounds with approximately 110 diﬀerent core structures and hundreds of
derivatives have been described [54]. Of these, around 54 % exhibit anti-
fungal and anti-yeast activity [55]. A prominent example of anti-fungal
myxobacterial products are the soraphens produced by S. cellulosum So ce26
(Fig. 1.4) [56]. The compounds are polyketide macrolactones, which incor-
porate an unusual, unsubstituted phenyl ring derived from benzoate [57].
Soraphen A, the most abundant derivative, exhibits strong activity against
yeasts and molds, combined with only a moderate activity towards mouse
ﬁbroblasts. These encouraging results led to further steps in the development
process towards utilization of soraphen as a plant-protective agent. Unfortu-
nately, toxicological test revealed a teratogenic activity in mice which ﬁnally
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led to the termination of the development project [58]. Nevertheless, the
mode-of-action of soraphen A remains novel, as it inhibits acetyl-CoA car-
boxylase (ACC), a biotin-dependent enzyme that catalyzes the carboxylation
of acetyl-CoA to produce the malonyl-CoA building block of fatty acids [59].
The biotin carboxylase domain of the ACC is blocked by soraphen which
ultimately leads to a complete loss of its catalytic function [60].
Figure 1.4: Chemical structures of natural products produced by myxobacteria.
Another Sorangium cellulosum strain, So ce12, is the producer of 26 diﬀerent
variants of the macrocyclic dilactone disorazol (Fig. 1.4) [61]. These com-
pounds show very high cytotoxicity towards animal cells. Mode-of-action
studies have demonstrated that disorazol A inhibits tubulin polymerization
and leads to the depletion of microtubules [62, 63]. This perturbation to the
microtubule network results in cell cycle arrest at the G2/M checkpoint and
induction of the apoptotic cell death cascade. Later on, the disorazoles have
also been discovered to be active in anti-viral screens as they modulate im-
portant host functions and thus, interfere with virus entry, traﬃcking, and
replication [64]. Recently, Rox et al. could show that the disorazols also
block invasion of group A staphylococci into human epithelial cells, leading
to eﬃcient irradication of the pathogen [65]
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Another high-proﬁle compound class from myxobacteria are the cystobac-
tamids produced by Cystobacter sp. Cb v34 [66]. The most potent derivative
cystobactamid 861-2 exhibited activity in the low µg mL-1 range against a
variety of Gram-positive and Gram-negative strains, thereby partly exceed-
ing the activity of ciproﬂoxacin [67]. The bacterial gyrase could be identiﬁed
as the molecular target of the cystobactamids. This enzyme changes the
spatial orientation the double-stranded DNA molecules prior to replication
or transcription. As the cystobactamids have been discovered fairly recently,
they are currently being subjected to extensive tests for the evaluation of
their full potential.
1.2.1 The Myxopyronins
In 2015, 1.8 million people died of tuberculosis, according to the World Health
Organization (WHO). This fact makes the infectious disease caused by My-
cobacterium tuberculosis one of the top 10 causes of deaths worldwide [68].
Due to the extensive treatment of tuberculosis using a combination of dif-
ferent antibiotics, ﬁrst cases of resistance of M. tuberculosis to rifampicin,
the antibiotic of choice, were reported in 1993 [69]. In 2015, 3.9 % of new
tuberculosis cases and 21 % of previously treated ones involved strains with
rifampicin or rifampicin/isoniazid resistance [68]. Consequently, there is an
urgent need for new antibacterial agents for the treatment of this wide-spread
disease. Among the promising substances are the myxopyronins, α-pyrone
natural antibiotics (Figure 1.5) produced by the gram-negative myxobac-
terium Myxococcus fulvus Mx f50 [70].
Figure 1.5: Chemical structure of the myxopyronins.
They target the switch region of the bacterial DNA-dependent RNA-
polymerase (RNAP) which is a diﬀerent site than the one targeted by the
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rifamycins, therefore avoiding cross-resistances (Fig. 1.6) [71, 72, 73].
Figure 1.6: Conformational stages of the RNAP showing the target sites for rifamycin and the switch
region targeted by myxopyronin [71].
Although there is no cross-resistance to RNAP inhibitors currently on the
market the frequency of resistance was calculated to be in the same range
as this of rifampicin [72]. Furthermore, mutations of the target region were
found that were induced by myxopyronin [74, 75]. This makes myxopyronin
in its native structure an undesirable candidate as an antibacterial agent.
However, myxopyronin is used as a model PKS-derived compound for
evaluation of the potential of heterologous expression of myxobacterial
products in Myxococcus xanthus.
1.2.2 The Vioprolides
Vioprolides are cyclic peptolides produced by the myxobacterium Cystobacter
violaceus, recently classiﬁed as Archangium violaceum, Cb vi35 [76, 77]. They
are remarkable examples for the structural diversity displayed by myxobacte-
rial natural products, as they are one of the very few compounds containing
an azetidine ring (Fig. 1.7). Furthermore, the structures contain unusual
amino acids. In vioprolide A (1) and B (2), one proline is replaced by a
pipecolic acid. In vioprolide A (1) and C (3), another proline is replaced by
a 4-methyl azetidine carboxylic acid (4-Maz).
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Figure 1.7: Chemical structure of the vioprolides. (1) vioprolide A, (2) vioprolide B, (3) vioprolide C
and (4) vioprolide D. The four derivatives are distinguished by the incorporation of either
L-pipecolic acid (blue) or L-proline (green), as well as either 4-methylazetidinecarboxylic
acid (red) or L-proline (orange).
The vioprolides exert antifungal as well as cytotoxic and immunomodulatory
activity [77, 78, 79]. Vioprolide D (4) shows the highest activity against a
variety of fungi and yeast with the least cytotoxicity against mammalian
cells, whereas vioprolides A-C (1-3) show a higher cytotoxicity and a lower
antifungal activity. The immunomodulatory activity is based on the ability
of these compounds to modulate the interferon response, involved in all kinds
of inﬂammatory or autoimmune diseases [78, 79]. The antifungal activity of
vioprolide D may also be even more important, since two of the three classes
of antifungal drugs used today (azoles and polyenes) have already been
launched in the 1980s with the third group, the echinocandins, having been
discovered at that time as well [80]. In contrast, the increased incidence rate
of invasive fungal infections that are in need of treatment can be correlated
with an expansion of the number of permanently immunocompromised
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patients, like those treated because of AIDS/HIV, cancer therapy or organ
transplantation [81]. Furthermore, strains of Candida albicans or Candida
glabrata with resistances to currently used drugs are emerging as well [82].
In this context, vioprolide D is a promising candidate for the treatment of
invasive fungal infections, as it combines antifungal and immunomodula-
tory activity. This is noteworthy, because it has been shown that type I
interferon-signaling mediates the lethal hyper-inﬂammatory response during
systemic infections of Candida albicans in the mouse model [83].
1.3 Natural Products Produced by the Genera Chitinophaga and
Flexibacter
The genus Chitinophaga was proposed by Sangkhobol & Skerman in 1981 to
include strains of ﬁlamentous, chitinolytic gliding bacteria that form spher-
ical rods upon aging [84]. The genus was assigned to the order of Sphin-
gobacteriales in the phylum Bacteriodetes. Soon after their identiﬁcation,
similarities between Sporophytophaga, Flexibacter and Chitinophaga strains
[85, 86] were pointed out which ﬁnally led to the re-assignment of several
Flexibacter and one Cytophaga strain to the genus Chitinophaga [87]. This
genus now comprises a number of heterogenous strains with regards to gliding
motility, habitat and chitinolytic activity. As the pyhlum of Bacteroidetes
is a subject to change and especially the genus Flexibacter is proposed to
be subdivided in to diﬀerent genera [88], the potential for the production of
natural products of these two genera is reviewed together.
Several β-lactam antibiotics with interesting modes-of-action were isolated
from Flexibacter strains (Fig.1.8). The formadicins from Flexibacter al-
ginoliquefaciens act selectively against pseudomonads and have proven
hydrolysis-resistant against various types of β-lactamases [89, 90]. The
monobactam SQ 28332 94 also belongs to the group of β-lactams from the
genus Flexibacter [91]. The dipeptides TAN-1057A-D produced by a Flex-
ibacter strain [92, 93] were shown to inhibit peptide elongation during bacte-
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rial translation due to inhibition of the peptidyl transferase reaction, thereby
possessing a diﬀerent binding site than other translational inhibitors [94].
Figure 1.8: Chemical structures of natural products produced by the genus Flexibacter.
Besides antibiotics, proteinase inhibitors were also found to be produced by
several Flexibacter strains, such as the human leukocyte elastase inhibitor
FR901451 103 [95, 96]. Two other elastase inhibitors, designated YM-47141
104 and YM-74142 105 are cyclic depsipeptides displaying a tricarbonyl moi-
ety which is suggested to be essential for their function [97, 98]. Compounds
isolated from Flexibacter topostinus were identiﬁed as lipid-containing amino
acids and peptides which were shown to suppress topoisomerase I activity and
were subsequently called topostins [99, 100, 101].
Chitinophaga strains have been isolated from carbon-rich soil samples around
the world [102, 103]. To date, only two groups of natural products have been
isolated from this genus, namely the pinensins from Chitinophaga pinensis
[104] and the elansolids from Chitinophaga sancti [105] (Fig. 1.9). But since
Wyatt et al. have found not yet annotated biosynthetic gene clusters in
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other Chitinophaga strains, the potential of this genus may have not been
fully discovered yet [106].
Figure 1.9: Chemical structures of natural products produced by the genus Chitinophaga.
The pinensins are lantibiotics that were found to be highly active against
many ﬁlamentous fungi and yeast but showed only a weak bacteriocidal ac-
tivity [104]. This is unusual, as lantibiotics are mostly produced by Gram-
negative bacteria and had thus far been found to act only against Gram-
negative bacteria [107]. Therefore, pinensins are regarded as the ﬁrst anti-
fungal lantibiotics.
1.3.1 The Elansolids
During the search for novel antibiotics, Steinmetz et al. found a group of
new macrolides, for which they proposed the trivial names, elansolids (Figure
1.10), in the culture extracts of the Gram-negative soil-dwelling bacterium
Chitinophaga sancti [105, 108].
Some of the elansolids exhibited moderate to strong activity against several
Gram-positive bacterial pathogens including methicillin-resistant Staphylo-
coccus aureus (MRSA). MRSA is at present the most commonly identiﬁed
antibiotic-resistant pathogen in many parts of the world with a prevalence
between 25 % and 50 % in most parts of America, Australia and southern
Europe [109, 110]. In 2005, 19,000 deaths associated with MRSA strains were
reported in the USA [111]. Although infection rates are decreasing, MRSA
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Figure 1.10: Chemical structures of elansolids. 1/1* = elansolid A1/A2, 2 = elansolid A3, 3 =
elansolid B1, 4 = elansolid B2, 5 = elansolid B3, 6 = elansolid C1, 7 = elansolid D1,
8 = elansolid D2.
infections were estimated to aﬀect more than 150,000 patients in the EU
alone in 2010 [112]. Until recently, vancomycin and daptomycin have been
the only eﬀective treatment for methicillin-resistant pathogens [113]. But
in 1997, the ﬁrst vancomycin intermediate-resistant S. aureus strains were
isolated, followed by reports of vancomycin resistant ones in 2003 [114, 115].
Cases of daptomycin-resistant MRSA have also been described [116, 117].
Consequently, the need for new antibiotics for the treatment of these multi-
resistant bacteria arises. In a global priority list released by the WHO in
2017, development of antibiotics against MRSA is given the second highest
priority [118]. To tackle this threat, eﬀorts are undertaken to ﬁnd new sub-
stances which can be developed as antibacterials.
Extensive chemical and biological studies revealed that elansolids A1 and
A2 (1/1*) occur as two distinct atropisomers. Both elansolids exhibit po-
tent activity against Gram-positive bacteria, elansolid A2 being generally
more active than elansolid A1. The MIC (minimal inhibiting concentration)
of elansolid A2 against methicillin-resistant S. aureus strain MRS3 is in the
range of 2 µg mL-1 [17]. Further studies revealed that the ﬁnal product of the
biosynthetic pathway is deoxyelansolid A3 (2) which undergoes lactonization
by an intramolecular Michael addition to yield elansolid A1/A2 [108, 119].
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Water, methanol or ammonia can also serve as nucleophiles that attack the
quinone methide moiety of elansolid A3 to generate elansolids B1-B3 (3-5)
and D1-D2 (7-8) [119] (Figure 1.11).
Figure 1.11: Interconversion of elansolids (adapted from [119]).
This reaction can be exploited in two diﬀerent ways: By adding diﬀerent
precursors as nucleophiles to the crude extracts of a C. sancti culture to
create new elansolid derivatives in a precursor-directed synthesis or by feed-
ing precursors such as anthranilic acid directly to the culture medium for a
directed biosynthesis (Figure 1.12). Interestingly, the bioactivities of these
newly formed derivatives were roughly in the same range as that of elansolid
A2 [120]. These results are promising as they possibly allow the creation
of precisely tailored derivatives with increased eﬃcacy, once mode of action
studies have revealed the target of the elansolids.
19
Figure 1.12: Reaction mechanism for the formation of elansolid C1 (6) by a Michael-type nucleophilic
attack of anthranilic acid on the p-quinone moiety of elansolid A3 (2). Anthranilic acid
can be substituted by other nucleophiles to yield the corresponding derivative.
1.4 Natural Product Biosynthesis
Most of the natural products relevant in clinical use today originate from
the secondary metabolism of the producer strain. They exhibit an ex-
traordinary chemical diversity which leads to a wide range of pharmaceu-
tical functions like antibiotics, immunosuppressants, antiparasitics, hypolipi-
demics and anti-tumoral agents [121]. In the majority of cases, the bioactive
compounds are the end products of complex multi-step biosynthetic pro-
cesses. Terpenes are the largest class of small-molecule natural products on
earth, and the most abundant by mass. They are built by plants, some
insects and fungi and are synthesized from dimethylallyl diphosphate and
isopentenyl diphosphate by diﬀerent prenyl transferases and terpene syn-
thases [122]. Besides the terpenes, there are giant multifunctional enzyme
systems called polyketide synthases (PKSs) and nonribosomal peptide syn-
thetases (NRPSs) that assemble secondary metabolites mostly from simple
building blocks such as coenzyme-A-activated carboxylic acids and amino
acids [123]. Although they utilize diﬀerent chemistries for activation and
condensation of their substrates, PKSs and NRPSs show striking similarities
in their buildup. This also leads to the fact that there are also PKS-NRPS
hybrid systems.
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1.4.1 Polyketide Biosynthesis
The diﬀerent types of PKS together with their building blocks and prominent
examples are listed in Table 1.3.
Table 1.3: List of the diﬀerent types of PKSs (adapted from [124]).
PKS type Building Block Organism Example
Modular type I
(non-iterative)
ACP, various exten-
der units (in situ
methylation possi-
ble)
Bacteria, protists Erythromycin [125]
Iterative type I ACP, only malonyl-
CoA extenders (in
situ methylation
possible)
Mainly fungi, some
bacteria
Lovastatin [126]
(Iterative) type II ACP, only malonyl-
CoA extenders
Exclusively bacte-
ria
Doxorubicin [127]
(Iterative) type III Acyl-CoA, only
malonyl extenders
Mainly plants, some
bacteria and fungi
Flavolin [128]
PKS-NRPS hybrid ACP, malonyl-CoA,
amino acids
Bacteria (modular),
fungi (iterative)
Epothilone [129]
Most of the natural products built by mxobacteria and other bacteria, like
these of the genus Chitinophaga, are synthesized by modular non-iterative
type I PKS (for exceptions of myxobacterial products, see reference [130]).
The biosynthesis of those polyketides resembles the formation of fatty acids.
The reactions are carried out by linearly arranged, covalently fused catalytic
domains paired up into functional modules. Each module contains a min-
imum of three domains required to catalyze one cycle of chain extension:
Ketosynthase (KS), acyltransferase (AT) and acyl carrier protein (ACP) as
well as a variable set of domains associated with keto group modiﬁcation (ke-
toreductase (KR), dehydratase (DH) and enoyl reductase (ER)) [131, 132].
Each domain is presumed to form a localized globular structure with a cat-
alytic role determined by conserved residues at its speciﬁc active site. The
domains are attached to each other by linker regions consisting of up to 100
amino acids. The number of modules usually correlates with the number of
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extension cycles executed by the PKS (principle of collinearity) [124]. The
presence of KR, DH and ER domains deﬁnes the degree of β-keto processing.
The gene sequences for the enzymes required to build one molecule are usually
in close promiximity to each other and are called biosynthetic gene cluster.
As the function of an enzyme is largely determined by its residues at the
active site, a genome sequence can be searched for these sequences in order
to identify novel biosynthetic gene clusters [133]. Sometimes, the module
architecture does not ﬁt with the resulting metabolite structure. This can
be due to the fact that at times modules are skipped or used more than
once, like in the case of stigmatellin [134, 135]. Another reason can be the
occurrence of PKS-subclass called trans-AT PKS. Here, the modules lack
individual AT domains. Instead, the ACPs are loaded by stand-alone ATPs
that are encoded on individual genes [136, 137].
In Figure 1.13 a schematic visualization of four modules of a type I PKS
is presented. The ﬁrst domain of the loading module (LM), namely the
acyl carrier protein (ACP), is usually loaded with one acetyl-CoA moiety
to start the biosynthesis. In some cases also bigger starting units can be
used, like propionyl-CoA for myxopyronin B [138]. Every ACP is natu-
rally an apoenzyme (inactive state) and must be activated by transferring
4-phosphopantetheine from co-enzyme A to a conserved serine of the ACP,
resulting in the holoenzyme (active state) [132]. This reaction is carried out
by a phosphopantetheinyl transferase. The ACPs of the following modules
are loaded with malonyl-extender units (originating from malonyl-CoA) with
the help of the AT. Instead of malonate, also methyl malonate, ethyl mal-
onate or other extender units can be used [139]. In trans-AT PKS systems,
the same trans-ATs are used iteratively to acylate each module which leads
to the consecutive incorporation of the same type of building block. In these
PKSs, methyl branches are therefore usually inserted by methyl transferases
(MTs) [136].
The growing chain is transferred from the ACP to the ketosynthase (KS).
This enzyme catalyzes a Claisen thioester condensation under carboxylation
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Figure 1.13: Schematic visualization of PKS biosynthesis. The ocher bubbles illustrate the individual
enzymatic domains which are organized in modules. The extended polyketide chain is
represented in brown, the extender units in black. EM3 shows the mechanism of chain
extension.
of C3 of the extender unit [121]. The C2 of the extender units initiates a
nucleophilic attack at the C1 of the chain bound to the KS. The elongated
chain is transferred to the ACP afterwards. EM1 (extender module 1) shows
the chain after the ﬁrst elongation step. C3 with the attached rest R1 derives
from the acteyl starting unit, whereas C1 and C2 with the attached rest R2
derive from the extender unit. EM1 is called a minimal extension unit be-
cause it consists only of a KS, AT and ACP module. EM2 on the other hand
is called a complete reductive loop because it additionally posses a KR, DH
and ER [140]. After chain elongation, the KR reduces the β-keto group to
an alcohol. The DH reduces the product again under elimination of water
to form a double bond (with cis- or trans-conﬁguration). Afterwards, the
ER carries out another reduction to form a single bond and with it a fully
saturated acyl backbone. When the required chain length is reached, the
chain is transferred to a thioesterase (TE) which releases it. At release often
an intramolecular cylcization occurs [141].
The products emerging of such a PKS pathway can be very complex because
with every step two stereo centers can be added. Additionally, conserved
protein cassettes have been discovered that catalyze the addition of methyl
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groups to the electrophilic β-carbon, a process called β-branching [139]. The
diversity can also be increased by post-PKS steps such as C-, O- and N-
glycolyzations, alkylations, acyl transfers, hydroxylations end epoxydations.
Other known modiﬁcations involve halogenation, transamination, nitrile for-
mation and desaturation to yield alkynes [142].
1.4.2 Non-Ribosomal Peptide Synthesis
The buildup of the Non-Ribosomal Peptides Synthetase (NRPS) resembles
this of the PKS because of its modular structure. The modules can also be
dissected into catalytic domains each being responsible for a speciﬁc step
during peptide synthesis. One elongation module contains at least three
essential domains: A condensation domain (C), an adenylation domain (A)
and a peptidyl carrier protein (PCP) (Figure 1.14A). An initiation module
comprises only the A-PCP domains.
The A-domain is responsible for the selection of the amino acids that make
up the product and thus controls the primary sequence of the peptide. The
speciﬁcity for a certain amino acid is encoded by up to eight amino acid
residues in the substrate binding pocket of the A-domain. Besides proteino-
genic amino acids, a plethora of non-proteinogenic amino acids is found to be
integrated which increases the structural diversity of the ﬁnal products [143].
A-domains activate amino acid substrates as amino acyl adenylate through
ATP hydrolysis [144]. Before this reactive intermediate can be further trans-
ported to the PCP-domain, the latter has to be activated by transferral of
the co-factor 4-phosphopantetheine (PPan) onto a conserved serine residue
of the PCP. The reactive amino acyl adenylate is then transported onto the
thiol moiety of the PPan. The holo-PCP is responsible for the transport of
the thioester bound substrates and all elongation intermediates between the
catalytic active sites and is therefore referred to as the `swinging arm' of each
NRPS module [145, 143]. In the next step of NRP-synthesis, the C-domain
catalyzes the peptide bond formation between amino acyl substrates bound
to PCPs of adjacent modules. The peptide bond formation is initiated by a
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Figure 1.14: A Schematic visualization of NRPS biosynthesis. The ocher bubbles illustrate the
individual enzymatic domains which are organized in modules. B shows the mechanism
of chain extension.
nucleophilic attack of the amino group of the activated amino acid bound to
the downstream (with respect to the C-domain) module onto the acyl group
of the amino acid tethered to the upstream module (Fig. 1.14B) [144]. The
resulting peptidyl intermediate is then translocated down the assembly line
for chain elongation and further modiﬁcation steps. These tailoring enzymes
fall into two categories: Some are integral parts of the NRPS and act in cis,
whereas others are distinct enzymes acting in trans.
A range of tailoring domains that are integrated into the elongation mod-
ules have been discovered. The most prominent ones are epimerization (E),
methylation (M), cyclization (Cy), oxidation (Ox), reduction (R) and formy-
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lation (F) domains [146]. E-domains catalyze the generation of D-amino acids
from their corresponding L-isomers. M-domains on the other hand use the
co-factor S-adenosyl-methionine for N- and C-methylation of speciﬁc amino
acid residues, thus making the peptide less susceptible to proteolytic break-
down [144]. In some NRPS modules that select cysteine, serine or threonine
residues, integrated Cy-domains catalyze a heterocylcic ring formation to the
corresponding thiazoline or oxaxoline rings in addition to peptide bond for-
mation. The heterocycles formed by the Cy-domains can be further catalyzed
to thiazole or oxazole rings by Ox-domains, whereas R-domains catalyze the
formation of thiazolidine or oxazolidine rings [145]. In some NP assembly
lines, like those for gramicidin, a F-domain is attached to the initiation mod-
ule that catalyzes the formylation of the ﬁrst amino acid [147]. In addition
to the modiﬁcations that occur during NRPS assembly by the integrated
tailoring domains, other modiﬁcations can also take place by independent
enzymes that temporarily associate with the NRPS template. Vancomycin,
for example, is cross-linked by oxidative cyclization of the phenolic side chain
by independet cytochrome P450-type heme proteins [148]. Afterwards, the
aglycon scaﬀold is decorated with sugar residues by an independent glyco-
syltransferase [149]. In many glyosylated NRPs, the sugars have a major
impact on their bioactivity [150].
In parallel to the PKS system, there are also examples where NRPS mod-
ules are used iteratively, which often leads to a symmetry of the product.
A further variation of the iterative mechanism is the nonlinear mode, which
relies on the fact that only one domain is used more than once during NRP
biosynthesis [143].
1.5 Heterologous Expression of Natural Products
One major drawback of myxobacterial compounds on their way to being de-
veloped as marketable products are the low product titers obtained from the
original producers. Total synthesis has already been achieved for some prod-
ucts [151, 152, 153] but remains daunting because of the variety of functional
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groups and multiple stereocenters that are characteristic to natural products,
resulting in low overall yields. Another approach to overcome this obstacle
is the expression of myxobacterial compounds in a heterologous host with
the aim of improved product concentrations. The ideal host should have the
following features [154, 155, 156, 157]:
• a relatively fast growth rate
• be suitable for bioreactor fermentations
• be amenable for genetic modiﬁcations
• the genome should be fully sequenced
• recognize all elements of the gene cluster to ensure functional expression
• have a broad precursor supply for NRPs and PKs (methylmalonyl-CoA,
propionyl-CoA, non-proteinogenic amino acids)
• have a similar GC-content resulting in a similar codon usage
• possess a broad range of 4'-phosphopantetheinyl transferases (PPTases)
for activation of the biosynthetic machinery
• have a minimal secondary metabolite background to lower the general
metabolic burden
• knowledge of gene cluster regulation, pathway interactions and
metabolic ﬂuxes should also be taken into account
The ﬁrst four requirements are met by the model organisms Streptomyces
coelicolor, Streptomyces lividans, Escherichia coli and Pseudomonas putida,
whereas the other favorable features are often met by strains that are phylo-
genetically closely related, but have better growth and genetic characteristics
than the original producers.
As genetic modiﬁcations of myxobacteria pose a challenge, especially since no
plasmids have been isolated so far, ﬁrst heterologous expression approaches
for the breast cancer lead compound epothilon from Sorangium cellulosum
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SMP44 were conducted with S. coelicolor CH999 [158]. S. coelicolor has a
doubling time of 2 h versus 16 h for S. cellulosum and is genetically well
understood. Because of its capability of endogenous polyketide production,
e.g. of actinorhodin, it was thought to be a suitable candidate. Neverthe-
less, only small quantities (50-100 µg L-1) were produced, possibly because
of cytotoxic eﬀects of epothilone on the host strain [158].
Production of soraphen A could be achieved in Streptomyces lividans after
augmentation of the host with a methoxymalonate-CoA and a benzoyl-CoA
biosynthetic pathway in addition to the soraphen gene cluster [159]. Here,
the yield was 300 µg L-1 and therefore six times lower than the initial titers
in the original producer Sorangium cellulosum So ce26 [56].
The use of E. coli, normally the ﬁrst choice for heterologous expression of
prokaryotic molecules, takes enormous eﬀort because ﬁrstly the GC content
and therefore the codon usage diﬀer signiﬁcantly to myxobacteria which can
lead to a non-eﬃcient expression and secondly E. coli lacks PPTases that
interact with modular PKS proteins [160]. These enzymes catalyze the co-
valent attachment of 4'-phosphopantetheinate derived from coenzyme A to
the peptidyl (for NRPS) or acyl (for PKS) carrier proteins, converting these
enzymes from the inactive apo- to the active holo-form. The endogenous PT-
Tases of E. coli are not able to carry out this reaction. Thirdly, the organism
is not able to provide the necessary precursors for PK and NRP synthesis.
The latter issues have been addressed by introducing the SFP PPTase from
Bacillus subtilis into the genome of E. coli and by engineering the host strain
to supply propionyl-CoA and methylmalonyl-CoA, PK precursors that are
uncommon in E. coli [161, 162]. By using this strain and by optimization of
codon usage, lowering of the cultivation temperature, co-expression of chap-
erones and splitting the largest protein into two polypeptides, Mutka et al.
were able to produce epothilone C and D, however only in concentrations of
about 10 µg L-1 [163].
Most of the undesirable characteristics of E. coli are circumvented when
utilizing Pseudomonas putida as the expression host. The advantages of
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P. putida are the fully sequenced genomes of important strains like KT2440
accompanied by numerous tools for genetic manipulation and gene expres-
sion as well as its high GC content similar to this of myxobacteria. Other
desirable features are a high tolerance towards xenobiotics due to its eﬀec-
tive eux system, a rather 'clean' metabolic background and the ability to
produce the precursors acetyl-CoA, propionyl-CoA and malonyl-CoA [164].
The major advantage however is the provision of a broad substrate range
with the ability to activate ACP and PCP domains [165]. The research
group of Rolf Müller has successfully expressed several myxobacterial prod-
ucts in P. putida KT2440. The ﬁrst product was myxochromide S from
Stigmatella aurantiaca DW4/3-1 with a product titer of 40 mg L-1 compared
to 8 mg L-1 in the original host [135, 166]. Unfortunately, the product was
not exported to the medium which poses a disadvantage for later puriﬁcation
steps. Another example is the expression of the PKS/NRPS hybrid gene clus-
ter of myxothiazol A also originating from Stigmatella aurantiaca DW4/3-1
[167]. After engineering the host strain into providing the necessary precursor
methlymalonyl-CoA, myxothiazol A concentration was 600 µg L-1 [168, 169].
The production of pretubulysin, originally from Cystobacter sp. SBCb004,
was achieved with a titer of 1.76 µg L-1 through exchange of the rare start
codon TTG and feeding of pipecolic acid [170, 171].
Reviewing these eﬀorts for heterologous expression of myxobacterial com-
pounds it becomes obvious that the results are far from satisfactory due to
the problems accompanying expression in non-related hosts. Another option
for achieving higher product titers is the expression in a phylogenetically
related strain with better growth characteristics. Myxococcus xanthus is to
date the best characterized myxobacterium with a fully sequenced genome
that possesses a considerably shorter doubling time with 5 h than e.g. So-
rangium cellulosum with 16 h [51, 172]. Furthermore, there is no engineering
of promoters necessary and biosynthetic precursors as well as PPTase are
intrinsically available. This is why M. xanthus was used in a number of
studies for the heterologous expression of myxobacterial compounds. After
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epothilone production in Streptomyces coelicolor yielded only small quanti-
ties, Julien & Shah reconstituted the gene cluster into the chromosome of
M. xanthus via homologous recombination. At ﬁrst, product concentrations
were also quite low, in the range of 500 µg L-1, but with media optimization
and a feeding strategy using casitone and methyl oleate, titers of 23 mg L-1
epothilone could be achieved, which is comparable to the original producer
[172, 173]. Interestingly, the ration between epothilon A and B was 1:10
as opposed to a ratio of 2:1 in the original producer Sorangium cellulosum
SMP44. Through a mutation of the epoK gene, epothilone C and D (the
most cytotoxic derivate) could be produced as well.
Besides homologous recombination other techniques like Red/ET recombi-
neering were employed to express the myxothiazol gene cluster with a concen-
tration of 20 mg L-1 [168]. To overcome the disadvantage of a comparatively
high metabolic background due to the production of endogeneous secondary
metabolites, the gene cluster was cloned into the myxovirescin cluster of M.
xanthus, thereby disrupting it and consequently reducing the metabolic bur-
den. Myxothiazol A had been isolated from diﬀerent strains of the genera
Angiococcus, Stigmatella and Myxococcus and rarely from the genera Cys-
tobacter and Corallococcus. Product titers in M. xanthus were comparable
to that of the native producers M. fulvus Mx f16 (mg L-1) and Stigmatella
aurantiaca DW4-3/1 (10 mg L-1) [167, 174]. Fu et al. transferred the myx-
ochromide S gene cluster from Stigmatella aurantiaca DW4-3/1 into M. xan-
thus using transposition with a ﬁnal titer of 500 mg L-1 which was 12.5 times
higher than in P. putida [135, 166, 175]. The bengamides, originally from
Myxococcus virescens ST200611 could also be produced in M. xanthus with
a concentration comparable to the original producer (5-10 mg L-1) [176, 177].
Aside from expression of pretubulysin in P. putida, the gene cluster was also
integrated into M. xanthus. The exchange of the rare start codon TTG to-
gether with feeding of pipecolic acid could increase the titer of pretubulysin
A to 190 µg L-1 which is more than tenfold the concentration achieved with
P. putida [171]. Furthermore, various disorazol compounds were expressed
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in M. xanthus with an overall yield of 400 µg L-1. Disorazol A was the main
derivative which is a ﬁve times higher concentration than in the original pro-
ducer Sorangium cellulosum So ce12 [61, 178].
These studies show that Myxococcus xanthus DK1622 has proven a suit-
able host for expression of myxobacterial secondary metabolites with product
titers comparable to or even better than those achieved by the original pro-
ducers. The order of Myxococcales is very inhomogeneous containing strains
with diﬀerent nutrition and growth proﬁles. Production of their metabolites
by large-scale fermentation is often necessary because of low titers but is hin-
dered by the diﬀerent demands posed by a variety of strains. These imped-
iments could be overcome when using Myxococcus xanthus as an expression
platform. But besides new techniques for gene transfer and engineering of the
translation machinery, it is also necessary to develop and optimize cultiva-
tion of M. xanthus to maximize the product titer and promote its beneﬁcial
characteristics.
1.6 Systematic Production of Natural Products
1.6.1 Discovery and Production of Antibacterial Compounds from Myxobacteria
The discovery and production of antibacterial natural products from myxo-
and other gliding bacteria follows a certain workﬂow that is depicted in Figure
1.15. First of all, the bacteria are isolated from soil samples. For this, the
nutritional preferences of the diﬀerent bacterial strains are harnessed. For the
isolation of bacteriolytic myxobacteria, E. coli cells on water agar are used,
while cellulose degraders are enriched on ﬁlter papers [30]. From there, single
colonies or swarms can be isolated and be transferred in liquid culture. The
culture is cultivated over several passages until a pure culture is obtained.
This type of small scale cultivation (up to 100 mL) is usually done in shake
ﬂasks, but alternatives like 50 mL falcon tubes with aerated lids or deep-well
micro-titer plates with covers like the Duetz-system are used as well [179].
The smaller cultivation volumes of these systems (around 10 mL) enable high
throughput screening. On the other hand, gliding bacteria tend to stick to
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the plastic walls of the smaller vessels which causes non-optimal nutrient and
oxygen supply.
Figure 1.15: Typical workﬂow for discovery and production of antibacterial natural products origi-
nating from myxobacteria.
The compounds produced by the bacteria are invariably excreted to the cul-
ture medium and in most cases captured on the hydrophobic adsorber resin
XAD16. The resin can be obtained through ﬁltration and extracted with or-
ganic solvents, usually methanol or acetone. This crude extract contains all
the compounds produced by the speciﬁc strain. It is subsequently subjected
to a bioactivity assay where it is tested against several diﬀerent organisms,
including Gram-positive and Gram-negative bacteria, yeasts and ﬁlamentous
fungi. If the crude extract inhibits the growth of any of the test strains, it
is fractionated with the help of a designated HPLC system and the fractions
are tested against the respective organism once again.
In parallel, the crude extract is injected into a high-resolution HPLC-MS/MS
system to record its mass spectrum. On the one hand, the retention time of
the peak that inhibited the bacterial growth can be matched to its mass de-
tected by the HPLC-MS/MS. On the other hand, the peaks' mass along with
the retention time can be checked against a database of known compounds,
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a process called dereplication. For myxobacteria, such a database was set up
by the Müller group at the Helmholtz Centre for Pharmaceutical Research
Saarland [180]. If the speciﬁc compound that caused the inhibition is yet
unknown, the next step is a large scale cultivation in bioreactors to obtain a
bigger amount for further testing. The subsequent experiments like structure
elucidation, target identiﬁcation and SAR studies require pure compounds,
so that at this point the product needs to be puriﬁed from the crude extract
by diﬀerent chromatography methods. The pure compound is also included
in a variety of test panels where it is tested for e.g. anti-viral or cytotoxic
activities.
Despite being such a rich source of natural compounds, there are not many
research groups around the world that study myxobacteria. This may origin
from their undesirable features in terms of handling and cultivation. They
have a very high doubling time with 4-14 h, compared to e.g. E. coli with
20 min [181]. Furthermore, they tend to form lumps and ﬂakes when growing
in liquid culture as well as sticking to only slightly rough surfaces, like stain-
less steel tubes or even bioreactor rotor blades. Additionally, most species do
not feed on carbohydrates, but require complex peptide sources or starch as
nutrients which calls for complex media and impedes mass balancing. How-
ever, one of the biggest challenges when dealing with myxobacteria are their
low product titers which are usually in the low mg L-1 range. This leads
to the fact that large-scale fermentations of 10-150 L cultivation volume are
required for almost every product in order to obtain an adequate amount
after puriﬁcation for subsequent experiments.
1.6.2 Bioprocess Engineering
Bioreactor cultivations bear several advantages over shake ﬂask cultivations.
These are all founded in the fact that a bioreactor presents a controlled
environment which increases the reproducibility of experiments drastically.
For shake-ﬂasks, the temperature can be controlled by setting a distinct
temperature in the incubator. The usage of HEPES as a buﬀer is supposed
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to keep the pH at a certain set-point. But in nearly every myxobacterial
shake ﬂask cultivation it can be observed that the pH becomes highly acidic
or alkaline during the course of the cultivation. The main parameter that
cannot be controlled in shake ﬂasks is the oxygen supply. This is highly
dependable on the shaking speed, the diameter of the shaking circle, the
ﬁlling volume and the gas diﬀusion through the plug of the shake ﬂask [182].
The ﬁrst three parameters can be kept constant between experiments, the
gas diﬀusion through the plug on the other hand diﬀers between shake ﬂasks.
The main reasons are the type of plugs used and how well the plug ﬁts on
the shake ﬂask [183].
Additionally, the oxygen transfer in shake ﬂasks is generally lower than in
bioreactors, because the gas transfer only occurs at the gas-liquid-interface
[184]. The gas-liquid-interface in bioreactors is much higher because the
air is supplied through a sparger that creates small bubbles (Figure 1.16).
The gas ﬂow can be also be controlled as well as the dissolved oxygen (DO)
concentration which is measured by a designated DO probe. The DO can be
kept at a certain set-point by regulation of the stirrer speed, gas ﬂow rate or
the addition of pure oxygen to the gas mix. The second probe common to
all bioreactors is the pH probe which is connected to acid and base pumps
through addition of which the pH can be kept at a constant level. One
major feature of a bioreactor is the process control system with which time-
or event-based proﬁles and online-monitoring for a variety of parameters can
be realized. The most common proﬁle is the feeding of nutrients after a
certain cultivation time in a continuous or non-continuous manner. This
type of cultivation process is called fed-batch fermentation.
Bioreactors exist in diﬀerent sizes and a variety of conﬁgurations. One of
the smallest commercially available single-use micro-scale bioreactor systems
is the ambr R© system of Sartorius Stedim with vessel sizes of 10-15 mL that
comes with a liquid-handling system [186]. The parallel-cultivation system
DASGIP R© of the Eppendorf company represents a fully-equipped bench-top
fermentation unit that allows exact pump rates due to microﬂuidic systems
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Figure 1.16: Schematic set-up of a bioreactor [185].
and parallel handling using an extensive process system (Figure 1.17). The
smallest reactor volume available is 60 mL (for the compatible DASbox R© sys-
tem). In situ autoclavable stainless steel bioreactors are available from 10 L
onwards up to several cubic meters. As the general build-up of bioreactors
stays the same throughout all sizes, the scalability of bioprocesses mainly
depends on the bioreactor geometry and the power input [187].
Despite the advantages of bioreactor systems, it can be assumed that proba-
bly more than 90 % of all culture experiments in biotechnology are performed
in shaking vessels [188]. This is mostly based on the easy handling resulting in
a high throughput. There are several companies tackling the problem of low
amount of information retrieved from small-scale shaken systems. One solu-
tion is represented by the BioLector R© system launched by m2p-labs which
is basically an automated micro-titer plate cultivation system with online-
monitoring of biomass, pH, DO, and ﬂuorescences [189]. The Pro version is
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Figure 1.17: Set-up of the parallel-cultivation system DASGIP R©. The vessels are harbored in the so-
called Bioblock that maintains the cultivation temperature. The gray blocks to either
side are the modules responsible for parameter control. The process control system is
operated via the DASware control software.
additionally equipped with continuous individual pH and feeding control. For
online-monitoring of shake ﬂask cultivations, the RAMOS (Respiratory Ac-
tivity MOnitoring System) by the company HiTec Zang enables OTR (Oxy-
gen Transfer Rate) and CTR (Carbon Dioxide Transfer Rate) measurements
as well as feeding control for up to eight shake ﬂasks in parallel [190]. These
inventions enable a higher reproducibility of small-scale shaken systems with
a higher information value and a more successful transfer of cultivation pro-
cesses to large-scale stirred tank bioreactors.
As mentioned above, myxobacterial cultivations usually yield only a small
amount of product. It is even more astonishing that only a few publications
deal with engineering and optimization of myxobacterial bioprocesses. Nutri-
tional requirements have already been studied as early as the 1960s but not
under the aspect of secondary metabolite production [191, 192, 193]. Addi-
tionally, the production of myxobacterial products using large-scale fermen-
tation has been reported for several products like corallopyronin, myxothia-
zol or the soraphens. But these processes were restricted to non-optimized
batch fermentations [56, 194, 174]. The ﬁrst account of optimization went
along with the commercialization of epothilone production in the early 2000s
which was implemented by heterologous expression in a M. xanthus strain.
The product titer was improved 140-fold with the use of the adsorber resin
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XAD16, the identiﬁcation of a suitable carbon source and the implemen-
tation of a fed-batch process [173]. Through reﬁnement of the fed-batch
fermentation into an optimized semi-continuous culturing system with opti-
mized bead retention times the yield could be increased even further [195].
In an eﬀort to control the derivative distribution of epothilones, the impor-
tance of controlling the DO level at a certain set-point was revealed. At an
excess oxygenation with a DO setpoint of 50 % epothilones A and B were
the most abundant derivatives while an oxygen depletion lead to the accu-
mulation of the pathway intermediates epothilones C and D [196], of which
epothilone D was the desired product. This phenomenon can be attributed to
the fact that epothilone D is processed by a cytochrome p450 monooxygenase
to form epothilone B. As the activity of these enzymes is oxygen-dependent,
it is hampered at low oxygen concentrations. The change of the metabolite
proﬁle at diﬀerent DO levels could also be observed by Hüttel & Müller who
optimized the fermentation of a Chondromyces strain using oﬀ-gas analysis
[197].
Bioprocess engineering comprises the optimization of media components as
well as fermentation parameters and feeding strategies. Optimization of the
media composition is done in most cases in shake ﬂasks by variation of one
media component in each ﬂask. This so-called one-factor-at-a-time ap-
proach bears the risk that the true optimal media composition is not reached
because the interactions of the components are not taken into account (Fig.
1.18A) [198]. This problem is circumvented by using statistical experimental
planning, also called Design of Experiments (DoE), the concept of mathe-
matical relationships between input and output variables of a system (Fig.
1.18B). Therefore, DoE avoids experimental bias with a simultaneous reduc-
tion of experiments compared to the number that would be necessary when
every factor would be combined with every other factor.
A full DoE optimization round contains three stages, as described in Figure
1.18C: In the ﬁrst stage, important factors are identiﬁed through a set of
experiments covering selected corners in the experimental space [200]. This
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Figure 1.18: A The ﬁgure shows how a quasi-optimum is achieved by varying one variable at a
time in an experimental setup with three factors. If only one factor is varied while the
others are kept constant, a correct optimum would never be reached as there could be a
dependency between the factors. B By simultaneous variations of the factors the whole
experimental space can be covered, as shown on the basis of a response surface design.
C The three stages of a full DoE round are shown including the designs recommended
for every stage (adapted from [199]).
procedure is called fractional factorial design, since only a fraction of the
possible values of the corners are investigated. This drastically lowers the
number of experiments that is deﬁned as N = 2n−k, where n is the number
of factors to be investigated and k is the number of steps to reduce the
experimental design. In addition to the corner experiments, center point
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experiments should be carried out in triplicate to determine the experimental
error of the responses. Typically, a few important factors are identiﬁed in
the ﬁrst stage which are then optimized using a full factorial design that
investigates all corners (2n experiments). For further reﬁnement and creation
of a valid model a response surface methodology with additional experiments
at the surface center points can be ensued as a third stage. The DoE approach
can be carried out with every type of controlled factor, like media components
or fermentation parameters. Additionally, the the inﬂuence of uncontrolled
factors can also be taken into account.
Several research groups in the ﬁeld of bioprocess engineering have reached
promising results using the DoE approach. Wang and co-workers optimized
the media composition for production of clavulanic acid with Streptomyces
clavuligerus by ﬁrst screening a variety of media ingredients by a two-level
fractional factorial design approach which was followed by optimizing the
levels of the media components by response surface methodology [201]. As
a result, the product yield could be increased by 50 %. Roebuck et al.
applied fractional factorial design and response surface modeling to determine
the optimal temperature and pH for the growth of the yeast Pachysolen
tannophilus [202]. An extensive overview of other applications is given in a
review by Mandenius & Brundin [200].
1.6.3 Metabolic Engineering
Increase of product yield in bioprocesses can also be achieved by metabolic
engineering techniques. These include targeted optimization of production
rates such as controlling or enhancing expression of pathway genes or increas-
ing the precursor supply for the biosynthesis of target compounds. Some of
these approaches are presented in Figure 1.19.
One strategy focuses on the identiﬁcation of regulators of secondary metabo-
lite biosynthesis in the speciﬁc organism. Once this has been successful,
targeted overexpression of positive or deactivation of negative regulators can
follow resulting in an overproduction of the desired compound. However,
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Figure 1.19: Schematic portrayal of genetic engineering approaches for secondary metabolite pro-
duction in myxobacteria [203].
this approach is complicated by the fact that regulators of myxobacterial
secondary metabolism are typically not co-localized with the biosynthetic
genes, unlike the situation in actinobacteria [203]. Nevertheless, two regula-
tory proteins were discovered that bind speciﬁcally to the chivosazole gene
cluster promoter region in S. cellulosum So ce56. ChiR was identiﬁed as
a positive regulator, overexpression of which resulted in ﬁve-fold increased
chivosazole titers [204]. NtcA on the other hand was shown to be a nega-
tive regulator. Its deactivation caused a four-fold increase in product yield
[205]. The inactivation of negative regulators in Angiococcus disciformis, re-
cently classiﬁed as Archangium disciforme [76], even led to a 30-fold higher
concentration of the PKS/NRPS product myxothiazol [206]. An alterna-
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tive strategy is the replacement of native by constitutive promoter elements.
The introduction of the constitutive tn5 promoter in front of a lipopeptide
biosynthetic gene cluster in M. xanthus eﬀectuated a 30-fold increase in the
concentration of myxochromide A [203]. These examples show that targeted
manipulation of the regulatory elements can be a powerful tool for bioprocess
optimization. However, high product titers can only be achieved if there is
no bottleneck in precursor supply. These include CoA-activated short chain
carboxylic acids for PK and amino acids for NRP biosynthesis. This requires
the analysis of metabolic ﬂuxes as done with S. cellulosum So ce56 [207].
One major goal when producing and investigating natural products are SAR
studies with the aim of understanding the eﬀect of the functional groups of
the molecule on pharmacokinetics and introducing new desirable properties.
A simple approach of creating new compounds is the feeding of unnatural
precursors to the fermentation culture which are taken up by the cells and
are incorporated into the target molecules. This process is called precursor-
directed biosynthesis. Examples are ﬂuorinated chondramide derivatives and
various anti-bacterial elansolid derivatives [120, 208]. One drawback of this
approach is that the unnatural precursors compete with the natural building
blocks, leading to a compound mixture. This problem is circumvented by
inactivation of the genes responsible for supply of starter units in combina-
tion with feeding of unnatural building blocks, termed as mutasynthesis. By
feeding various unnatural starter molecules to a M. xanthus mutant strain, it
was possible to generate nine novel myxalamid derivatives [209]. Generation
of new myxopyronin derivatives was also achieved by Sahner et al. for another
M. xanthus mutant strain, although product titers were very low with 1-10
µg L-1 [210]. This studies lead to the ultimate aim of combinatorial biosyn-
thesis, the altercation of PKS/NRPS product molecular structures through
editing of the biosynthesis gene cluster itself through genetic engineering.
Although direct modiﬁcations of the PKS/NRPS backbone in myxobacte-
ria has not been successful yet, promising results for other organisms exist
[211]. However, inactivation of genes encoding post-assembly line process-
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ing enzymes led to the formation of multiple derivatives in myxobacterial
strains for the adjuzoles in C. crocatus [212], stigmatellin in S. aurantiaca
[167] and spirangien in S. cellulosum [213]. As genetic engineering tools and
techniques will expand and ameliorate in the future, these approaches could
one day become the future of pharmaceutical research.
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2 Material and Methods
2.1 Bacterial strains
For elansolid production, the strain Chitinophaga sancti Fx7914 was used.
For myxopyronin production, the myxopyronin A gene cluster was integrated
into the genome of Myxococcus xanthus DK1622 ∆mchA-tet via Red/ET
recombination according to [214]. The ﬁnal strain used in this study was
termed M. xanthus DK1622 ∆mchA-tet::pHSU-mxn43.
For vioprolide production, the vioprolide gene cluster was integrated into the
genome ofMyxococcus xanthus DK1622 (∆mchA) via Red/ET recombination
according to [215]. The ﬁnal strain used in this study was termed M. xanthus
DK1622 ∆mchA-tet::Ptn5-vio.
2.2 Media and supplements
Chitinophaga seed culture medium
For seed-cultures, medium (10.0 g L-1 soy peptone (Cargill), 1.0 g L-1
CaCl2·2 H2O, 1.0 g L-1 MgSO4·7 H2O, 8.0 mg L-1 Na-Fe-EDTA, 11.9 g L-1
HEPES; pH 7.4) was used to which maltose monohydrate was added after
autoclaving to a ﬁnal concentration of 10.5 g L-1.
Chitinophaga production medium
Bioreactor cultivations were conducted with a production medium (1.99 g L-1
(NH4)2SO4, 700 mg L-1 KH2PO4, 200 mg L-1 MgSO4·7 H2O, 8.0 mg L-1 Na-
Fe-EDTA, 5.0 mg L-1 MnSO4·H2O, 1.0 mg L-1 ZnCl2; pH 7.0) to which the
carbon sources were added after autoclaving giving the following ﬁnal con-
centrations: 10.0 g L-1 sucrose; 10.1 g L-1 glucose monohydrate. To enable
elansolid C1 production an anthranilic acid solution in methanol was pre-
pared through sterile ﬁltration and added to the bioreactor before inoculation
to give a ﬁnal concentration of 100 µg L-1. To capture the metabolites am-
berlite XAD16 resin (Sigma) was added to all production media to a concen-
tration of 20 g L-1. Feed solutions contained 440 g L-1 glucose monohydrate
43
and 146.7 g L-1 (NH4)2SO4 that were autoclaved separately and afterwards
merged to add up to 500 mL.
Myxococcus agar plate medium
For agar plates, a medium consisting of 10.0 g L-1 Bacto Casitone (Becton
Dickinson), 1.97 g L-1 MgSO4·7 H2O, 136.1 mg L-1 KH2PO4, 1.21 g L-1 Tris,
15.0 g L-1 Bacto Agar (Becton Dickinson) (pH 7.4) was used. Sterile ﬁltered
kanamycin monosulfate was added to a ﬁnal concentration of 50.0 mg L-1
after autoclaving.
Myxococcus seed culture medium
For seed cultures, a medium consisting of 10.0 g L-1 Bacto Casitone (Becton
Dickinson), 1.97 g L-1 MgSO4·7 H2O, 136.1 mg L-1 KH2PO4, 11.9 g L-1
HEPES (pH 7.4) was used. Sterile ﬁltered kanamycin monosulfate was added
to a ﬁnal concentration of 50.0 mg L-1 after autoclaving.
Myxopyronin production medium
The standard production medium consisted of 20 g L-1 skim milk pow-
der (supplier unknown), 6.6 g L-1 glucose monohydrate, 4.0 g L-1 fructose,
2.0 g L-1 yeast extract (Ohly Kat), 1.0 g L-1 CaCl2·2 H2O, 1.0 g L-1 MgSO4·7
H2O (pH 7.5). For testing diﬀerent media components, the skim milk powder
was substituted by 6.31 g L-1 lactose monohydrate and 14.0 g L-1 of either
casein (Alfa Aesar), Bacto Casitone (Becton Dickinson), casamino acids (Bec-
ton Dickinson), bacteriological meat peptone (Organotechnie), yeast extract
(Ohly Kat) or soy peptone (type II, Marcor). The bioreactor fermentations
were either carried out with the standard production medium or with meat
peptone production medium consisting of 20 g L-1 bacteriological meat pep-
tone (Organotechnie) and 6.31 g L-1 lactose monohydrate instead of 20 g L-1
skim milk powder. For the fed-batch fermentation, the feed (500 mL) con-
sisted of 60 g L-1 bacteriological meat peptone (Organotechnie), 6.31 g L-1 lac-
tose monohydrate, 6.6 g L-1 glucose monohydrate, 4.0 g L-1 fructose, 2.0 g L-1
yeast extract (Ohly Kat), 1.0 g L-1 CaCl2·2 H2O, 1.0 g L-1 MgSO4·7 H2O (pH
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7.5). To every production medium sterile ﬁltered components were added af-
ter autoclaving to ﬁnal concentrations of 8.4 mg L-1 FeCl3·6 H2O, 0.1 mg L-1
vitamin B12 and 50.0 mg L-1 kanamycin monosulfate.
Vioprolide production medium
The standard production medium consisted of 20 g L-1 skim milk pow-
der (supplier unknown), 6.6 g L-1 glucose monohydrate, 4.0 g L-1 fructose,
2.0 g L-1 yeast extract (Ohly Kat), 1.0 g L-1 CaCl2·2 H2O, 1.0 g L-1 MgSO4·7
H2O, 11.9 g L-1 HEPES (pH 7.5). For testing diﬀerent media components,
the skim milk powder was substituted by 6.31 g L-1 lactose monohydrate and
14.0 g L-1 of either casein (Alfa Aesar), Bacto Casitone (Becton Dickinson),
bacteriological meat peptone (Organotechnie), yeast extract (Ohly Kat) or
soy peptone (type II, Marcor). For bioreactor cultivations, no HEPES was
used. To every production medium sterile ﬁltered components were added af-
ter autoclaving to ﬁnal concentrations of 8.4 mg L-1 FeCl3·6 H2O, 0.1 mg L-1
vitamin B12 and 50.0 mg L-1 kanamycin monosulfate, in addition to sepa-
rately autoclaved amberlite XAD16 adsorber resin (Sigma) with a ﬁnal con-
centration of 20 g L-1. The supplemental amino acids were added to the
production culture after 48 h with a ﬁnal concentration of 100 mg L-1.
2.3 Cultivation Conditions
Chitinophaga shake ﬂask cultivations
250 mL shake ﬂasks containing 100 mL pre-culture medium were inoculated
with 1.8 mL cryo stock and incubated at 25 ◦C and 160 rpm for 24 h. From
this seed-culture, bioreactors were inoculated to a concentration of 10 g L-1.
Myxococcus shake ﬂask cultivations
500 µL of a cryo stock were plated on an agar plate and incubated for 96 h
at 30 ◦C. For seed culture, each 250 mL shake ﬂask without baes con-
taining 50 mL seed-culture medium was inoculated with 5 agar plugs (each
0.5 mm in diameter). The seed-culture was incubated for 48 h at 160 rpm
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and 30 ◦C. The production cultures (250 mL shake ﬂask without baes con-
taining 50 mL production medium) were inoculated with 5 % seed-culture
and were incubated for 148 h at 160 rpm and 30 ◦C.
Bioreactor cultivations
All bioreactor cultivations were performed with the parallel cultivation
system DASGIP (Eppendorf) and DASware control 5 for process control.
The vessels had a total volume of 2.0 L. The system was equipped with
optical DO electrodes (Hamilton) and pH electrodes (Hamilton). The oﬀ-gas
analyzer consisted of zirconium dioxide sensors for O2 measurement and
infrared sensors for CO2 measurement (BlueSens). The DO concentration
in the medium was kept at a constant level of 20 % by increasing the stirrer
speed (200-1200 rpm) and adding pure oxygen to the gas mix if necessary,
realized by an internal cascade. The gas ﬂow rate was kept constant at
0.05 vvm. The pH level was kept constant as well by the addition of 50 g L-1
H2SO4 or 50 g L-1 acetic acid (for myxopyronin production) and 50 g L-1
KOH. When foaming occurred, Tegosipon anti foam (Evonik) was added
with a 1 mL syringe.
For Chitinophaga cultivations, the pH was set at 7.0. The batch fermenta-
tions were started with a cultivation volume of 1.5 L and lasted 85 h. The
fed-batch fermentations were started with a cultivation volume of 1.0 L and
lasted 94-190 h. The feed was started after 48 h for the sucrose glucose
fermentation and after 24 h for the glucose glucose fermentations with a
feeding rate of F=2.04·e0.056·t mL h-1.
For mxyopyronin and vioprolide production, the pH was set at 7.5. The
cultivation volume was 1.5 L and the bioreactors were inoculated with 5 %
seed-culture. In the myxoypronin fed-batch fermentation, the feed was
started 96 h after inoculation and was kept at a constant speed of 5 mL h-1
for another 96 h.
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2.4 Accompanying Analytics
Determination of optical density and substrate concentration
Optical density was determined with a Libra S11 photometer (Biochrom) at
λ=600 nm. Samples were diluted to be in the linear range of the photometer.
Sucrose concentrations and corresponding monomeric glucose and fructose
were determined with a photometric assay kit from r-biopharm (art. no.
10716260035). For measuring of glucose and lactose concentration, a second
method was applied using an Agilent 1260 series HPLC and a Phenomenex
REZEX ROA-Organic Acid H+ (8 %) column (300 mm x 7.8 mm x 8 µm)
at 65 ◦C with a RID detector and an isocratic gradient of 0.05 mM H2SO4
for 45 min.
Determination of elansolid concentration
After sample taking the amberlite XAD16 was ﬁltered through gauze. The
residual resin was weighed and the 10-fold volume (w/v) of a 1 % acetic acid
solution in acetone (v/v) was added to the resin. After 10 min of incubation
on a horizontal shaker 1 mL supernatant was centrifuged at 20,000 g for
10 min. The supernatant was injected in to an Agilent 1200 Series HPLC
with a Waters Acquity UPLC BEH C18 column (50 mm x 2.1 mm x 1.7 µm)
at 40 ◦C using 0.01 % formic acid in water (v/v) and 0.01 % formic acid in
acetonitrile (v/v) as mobile phase. The gradient went linearly from 5 % to
100 % acetonitrile in 20 min. The UV signals were detected at λ=220 nm.
The product concentrations were determined via a calibration curve using 5
deﬁned standard solutions.
Determination of myxopyronin concentration
1 mL of the culture was centrifuged at 20,000 g for 10 min. 500 µL of ice-
cold methanol were added to 500 µL supernatant and the solution was mixed
thoroughly. Afterwards, it was centrifuged again at 20,000 g for 5 min. The
supernatant hereof was injected in to an Agilent 1200 Series HPLC with a
Waters Acquity UPLC BEH C18 column (50 mm x 2.1 mm x 1.7 µm) at
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40 ◦C using 0.01 % formic acid in water (v/v) and 0.01 % formic acid in
acetonitrile (v/v) as mobile phase. The gradient went linearly from 5 % to
100 % acetonitrile in 20 min. The UV signals were detected at λ=220 nm.
The product concentrations were determined via a calibration curve using
ﬁve deﬁned standard solutions.
Determination of vioprolide concentration
After sample taking the amberlite XAD16 was ﬁltered through gauze. The
residual resin was weighed and the 10-fold volume of methanol was added to
the resin. After 30 min of incubation on a horizontal shaker 1 mL supernatant
was centrifuged at 20,000 g for 10 min. The supernatant was injected in to an
Agilent 1200 Series HPLC with a Waters Acquity UPLC BEH C18 column
(50 mm x 2.1 mm x 1.7 µm) at 40 ◦C using 0.01 % formic acid in water (v/v)
and 0.01 % formic acid in acetonitrile (v/v) as mobile phase. The gradient
went linearly from 5 % to 100 % acetonitrile in 15 min. The UV signals were
detected at λ=220 nm. The product concentrations were determined via a
calibration curve using 5 deﬁned standard solutions.
Serial dilution assay for determination of antibacterial activity
Minimum inhibitory concentration (MIC) values were determined in standard
microbroth dilution assays as described in [216]. In brief, bacterial suspen-
sions of Escherichia coli DSM-1116 and TolC-deﬁcient E. coli were prepared
in Müller-Hinton broth (104-105 cfu mL-1). In addition, the eux-deﬁcient
E. coli strain was permeabilized with polymyxin B nonapeptide (PMBN) at
a sub-inhibitory concentration (3 µg mL-1) and used for testing following the
same procedure. Given MIC values are the lowest concentrations of antibiotic
at which there was no visible growth.
2.5 Design of Experiments Setup
For the setup and evaluation of the Design of Experiments runs, the software
MODDE (Version 9.0.0.0) was used. Since the goal of these experiments
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was the screening of diﬀerent fermentation parameters, a fractional factorial
design was used. Using this design with four factors resulted in eight runs
plus three center point-runs (Table 3.2). The center points are the mean
values of the extreme values of the investigated factors.
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3 Results
The aim of this thesis is the investigation of the production capacity of
myxobacteria and gliding bacteria of the genus Chitinophaga. As stated
above, there is a need for novel drugs for the treatment of infectious and
other diseases that are only partially met by compounds of synthetical origin.
Thus, natural compounds with desirable properties and promising modes-of-
action are indispensable if a post-antibiotic era should be avoided. Myxo-
and other gliding bacteria play an important role as producers of bioactive
compounds with new modes-of-action. The demand for sophisticated han-
dling of these bacteria due to long cultivation times and special nutritional
requirements calls for a certain expertise that leads to the fact that in the
past myxobacteria have been neglected by the pharmaceutical industry as
sources of new drugs. One point that plays a major role in this context are
low product titers achieved through bioreactor cultivation of these organisms.
In this thesis, the problem of low product titers is tackled in three diﬀerent
projects.
The ﬁrst project covers the biotechnological production of the compound
group of elansolids, anti-MRSA agents produced by the gliding soil-dwelling
bacterium Chitinophaga sancti. The other two projects deal with the het-
erologous production of PKS- and NRPS-derived molecules with the model
myxobacterium Myxococcus xanthus. The investigation of possible advan-
tages of heterologous expression over production with the natural producer
is thought to be a step towards the use of M. xanthus as an universal expres-
sion platform for certain classes of natural compounds.
With the exception of the elansolid bioactivity assay which was carried out
by Viktoria Schmitt at the Helmholtz Institute of Pharmaceutical Research
Saarland, all of the experiments were planned, performed and evaluated by
the author of this thesis.
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3.1 Production of Elansolids with Chitinophaga sancti Fx7914
To turn the highly interesting class of elansolids (see Chapter 1.3.1) into a
lead for pharmaceutical development, it will be necessary to improve both
their stability and potency. This compound class is amenable to various
structural modiﬁcations by means of medicinal chemistry. However, for this
purpose, the yields from biotechnological production need to be improved,
in order to provide access to the starting material in multi gram scale. Elan-
solid A3, which has hitherto been used as starting material for semi-synthesis
approaches is highly unstable. The rationale to direct the biotechnological
production in order to allow for easy access of the starting material for a
subsequent medicinal chemistry program is that it should be more feasible
to produce elansolid A2. The latter compound can be converted back to
elansolid A3 under mild conditions [105, 119]. For this reason, the biotech-
nological production of elansolid A2 with C. sancti was investigated in this
study. One drawback of the biotechnological production has so far been the
formation of several side products  especially in complex media - due to the
reactivity of the elansolids A1-A3, which signiﬁcantly lowered the yield of
elansolid A2 in such a process. The reduced yield in undeﬁned media arises
from unspeciﬁc side reactions with either nucleophilic media components or
intermediates, which are released by the producer itself due to cell lysis oc-
curing in complex media when toxic metabolites accumulate. This might be
circumvented by reducing formation of toxic metabolites and increasing the
viability of the producer with the usage of a deﬁned media and by concur-
rently directing the product formation towards a stable derivative through
feeding of the corresponding precursor. The feasibility of this precursor-
directed approach was explored in this study by feeding anthranilic acid, the
precursor of elansolid C1 (6) which was shown to be incorporated in vivo
and could thereby serve as a model system for direct incorporation of se-
lected building blocks during the production process.
In previous studies, the activity spectrum of the elansolids was determined
to include only Gram-positive bacteria, like Staphylococcus aureus. To val-
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idate if the molecular target of the elansolids also exists in Gram-negative
organisms and activity is reduced by reduced membrane diﬀusion or eux,
a bioactivity assay with the secretion-deﬁcient E. coli tolC in combination
with the membrane-permeabilizing peptide PMBN was performed revealing
that elansolids A2 and C1 inhibit this gram-negative strain with 2 µg mL-1
and 8 µg mL-1, respectively (Table 3.1). Following this logic, the elansolids
presumably act on the same molecular target in gram-positive and gram-
negative bacteria, but cannot penetrate the membrane of Gram-negatives
[217].
Table 3.1: Minimum inhibitory concentrations (MIC) in µg mL-1 of elansolids A2 and C1 against
diﬀerent E. coli strains.
Strain Elansolid A2 Elansolid C1
E. coli DSM1116 >64 >64
E. coli TolC 64 64
E. coli TolC+PMBN 2 8
According to Steinmetz et al., it is crucial to use a deﬁned medium without
complex media components when producing elansolid A2 because otherwise
elansolid C1, a derivative containing anthranilic acid, is produced instead
of elansolid A2 [120]. A deﬁned medium was developed for which sucrose
was found to be the most suitable carbon source for elansolid A2 production
during shake ﬂask experiments with an elansolid A2 concentration of around
18 mg L-1 (data not shown).
The results were transferred to bioreactor scale, where a batch fermentation
in the minimal medium with sucrose as carbon source was conducted (Fig-
ure 3.1). The disaccharide sucrose was metabolized right from the beginning,
but released fructose accumulated in the medium until 61 h after inocula-
tion when the concentration had its highest value with 2.7 g L-1. Released
glucose could only be detected at the beginning of the fermentation with
a concentration of 0.18 g L-1 until 13 h (0.03 g L-1) after inoculation but
vanished within less than 24 h. This indicates that sucrose was probably
digested by extracellular invertases and glucose was taken up preferentially
by the cells until sucrose was depleted. Afterwards, the remaining fructose
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was metabolized. After 18 h, a change from exponential to limited growth
could be observed, as indicated by the CTR (carbon dioxide transfer rate)
(Figure 3.1a). This might be due to cleavage of sucrose and supply of glucose
as a limiting factor. After 37 h elansolid A2 production could be detected
with a sigmoidal increase until the end of the cultivation to a ﬁnal value
of 18.9 mg L-1 comparable to the shake ﬂask experiments. As illustrated
in Figure 3.1c, elansolid A2 is not the only derivative produced. In fact, it
accounted for only 14 % of the total elansolid yield based on the peak areas
of the HPLC runs where the sum of all peak areas is accounted for as 100 %.
The main product is elansolid B1 (water addition to elansolid A3). Although
elansolid A3 is unstable in an aqueous environment it can still be detected,
presumably due to slow reaction kinetics or possible protection when bound
to the adsorber resin. Besides the published elansolid derivatives there are
also several others, which are detectable in minor amounts but together make
up a substantial fraction of the overall elansolid yield.
The batch process with sucrose did not lead to an increase in elansolid A2
concentration compared to the shake ﬂask cultivation. Hence, as a next step
towards the aim of improved elansolid A2 yield, a fed-batch fermentation
was conducted. Sucrose was provided in the medium at the beginning of the
fermentation with a concentration of 20 g L-1, using the starting conditions of
the batch fermentation. Due to preferred utilization of glucose by C. sancti
in the previous experiment, this sugar was chosen as substrate in the feeding
solution. The fermentation was started as a batch cultivation and after 48 h
an exponentially increasing glucose feed was started. As seen in Figure 3.2,
the curve-progression of the illustrated parameters develops similarly to the
batch fermentation until the feed was started after 48 h, also exhibiting the
transition from exponential to linear growth after 18 h. After starting the
feed the CTR rapidly increased from 2.4 mMol h-1 to 12.3 mMol h-1 after 59 h.
The elansolid A2 concentration increased until 74 h to 55.3 mg L-1 resulting in
a 2.9-fold increase in comparison to the batch fermentation. As in the batch
fermentation, several elansolid derivatives were produced of which elansolid
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Figure 3.1: a Course of carbon dioxide transfer rate (CTR), free glucose concentration and b sucrose,
free fructose and elansolid A2 concentrations and c peak areas of elansolid derivatives
from the HPLC runs throughout the bioreactor batch fermentation of C. sancti with
sucrose as carbon source.
A2 made up only 15 % of the overall yield (Figure 3.2c).
Since sucrose as carbon source caused a diauxic growth of C. sancti, a second
fed-batch fermentation with glucose as sole carbon source in batch and feed-
phase was conducted (Figure 3.3). The feed was started after 24 h. The CTR
increased exponentially in the ﬁrst 28 h after which a small dent occurred
which correlates with the starting point of elansolid A2 production. Following
the dent, the CTR increased linearly to 21.0 mMol h-1 in average from 48 h
to 116 h. The oscillation of the CTR is caused by the fact that whenever
the culture becomes more acidic, carbon dioxide that was formerly dissolved
in the medium is released. When the pH is regulated by adding potassium
hydroxide more carbon dioxide can be dissolved again. Therefore, these
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Figure 3.2: a Course of carbon dioxide transfer rate (CTR) and free glucose concentration, b sucrose,
free fructose and elansolid A2 concentrations, c peak areas of elansolid derivatives from
the HPLC runs throughout the bioreactor fed-batch fermentation with sucrose in the
basal medium and glucose in the feed solution. The gray areas represent the duration of
feeding.
ﬂuctuations do not represent the true carbon dioxide emission rate (CER),
a problem that has been addressed by several publications before [218, 219,
220]. The elansolid A2 concentration increased to 34.4 mg L-1 after 67 h
which was less than in the fermentation with sucrose in the starting medium
(end concentration was 31.8 mg L-1). This is due to the fact that elansolid
C1 was detected in high concentrations from 67 h onwards which was so far
only encountered when complex substrates were present in the medium [120].
The ﬁnal concentration of elansolid C1 was 223.1 mg L-1 and accounted for
32 % of all derivatives.
The accumulation of undesired side products in all cultivations for elansolid
A2 production justiﬁed the investigation of a process aiming for the exclusive
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Figure 3.3: a Course of carbon dioxide transfer rate (CTR) and free glucose concentration, b sucrose,
free fructose and elansolid A2 concentrations, c peak areas of elansolid derivatives from
the HPLC runs throughout the bioreactor fed-batch fermentation with glucose in the
basal medium and glucose in the feed solution. The gray areas represent the duration of
feeding.
production of a single derivative. As a model system elansolid C1 was chosen
since the precursor is readily available and C1 has similar activities as A1/A2
[120]. So far, the directed biosynthesis of elansolid C1 with complex medium
yielded product titers with concentrations of around 7.1 mg L-1 in batch-
fermentations [120]. To show the feasibility of the directed biosynthesis of
elansolid C1 in deﬁned medium, a fed-batch fermentation with anthranilic
acid supplementation to the medium was conducted. The results are shown
in Figure 3.4. The respirational activity, represented by the CTR, reached an
average of 14.3 mMol h-1 from 48 to 120 and therefore only 68 % of the CTR
of the fed-batch with glucose as sole carbon source without anthranilic acid
(Figure 3.3). As a consequence of the reduced metabolic activity, glucose
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accumulated to a ﬁnal concentration of 77.5 mg L-1. First elansolid C1 was
detected after 17 h followed by an exponential increase with a maximum
titer of 252.7 mg L-1 after 115 h. In this fermentation, the desired derivative
elansolid C1 made up the major portion of the total yield with 85 % based
on the peak areas.
Figure 3.4: a Course of carbon dioxide transfer rate (CTR) and free glucose concentration, b su-
crose, free fructose and elansolid A2 concentrations, c peak areas of elansolid derivatives
from the HPLC runs throughout the bioreactor fed-batch fermentation with glucose and
anthranilic acid in the basal medium and glucose in the feed solution. The gray areas
represent the duration of feeding.
3.2 Heterologous Production of Myxobacterial Products with
Myxococcus xanthus DK1622
One major drawback of myxobacterial compounds on their way to being de-
veloped as marketable products are the low product titers obtained from the
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original producers. In an attempt to increase the production, the gene clus-
ters of several myxobacterial products were cloned into diﬀerent host organ-
isms, e.g. Streptomyces lividans [159], Escherichia coli [163], Pseudomonas
putida [168, 171] and Myxococcus xanthus [175, 177, 178]. M. xanthus is
the most-studied myxobacterium and combines several advantages for the
heterologous expression of myxobacterial natural products through the close
genetical relatedness. The most important requirements for functional ex-
pression of these compounds are considered to be a similar codon usage,
recognition of all gene cluster elements, precursor supply and provision of
enzymes for the activation of the biosynthetic machinery [155, 156, 157]. Af-
ter successes with other myxobacterial products where product titers were
throughout higher than in the natural producers [175, 177, 178], the myx-
opyronin and the vioprolide biosynthetic gene clusters were cloned into M.
xanthus DK1622 [214, 215].
3.2.1 Heterologous Production of Myxopyronin A
The order Myxococcales is very diverse and comprises genera with a vari-
ety of nutritional requirements. Species of the genus Myxococcus can only
metabolize peptides as they feed on other bacterial cells in their natural envi-
ronment [192, 193]. Thus, when using Myxococcus xanthus as an expression
host, one has to create a medium that combines optimal cell growth with
desirable physicochemical characteristics. The medium that was used for
the initial shake ﬂaks cultivations of M. xanthus DK1622 contains skim milk
which consequently leads to a turbid medium that also coagulated during au-
toclaving and therefore is not suitable for large-scale cultivation. Thus, one
focus of this study was the development of a nutrition medium without any
non-soluble components to facilitate bioreactor cultivation and compound
puriﬁcation.
Besides skim milk powder, which was the original CN-source, various com-
ponents of skim milk in diﬀerent hydrolyzation grades were tested, as well as
meat peptone and peptones derived from non-animal origin. Through HPLC
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measurement, it could be shown that the skim milk powder consisted of 30 %
lactose (data not shown). In order to keep the composition of the diﬀerent
media as equal as possible, the 20 g L-1 skim milk were substituted with
6 g L-1 lactose and 14 g L-1 of the complex CN-source. For the evaluation of
the eﬀect of diﬀerent CN-sources on the product concentrations, shake ﬂask
cultivations were performed, of which the results can be seen in Figure 3.5.
Figure 3.5: Myxopyronin A concentration of shake ﬂaks cultivations after a cultivation time of
148 h for media with diﬀerent complex CN-sources. The cultivations were done in
triplicates; the error bars represent the standard deviation. SM=skim milk, CS=casein,
CT=casitone, CA=casamino acids, MP=meat peptone, YE=yeast extract, SP=soy pep-
tone.
The use of the standard medium containing skim milk (SM) resulted in a
myxopyronin A concentration of 27.8 mg L-1, similar to this when using ca-
sein (CS) (26.5 mg L-1). Casitone is the pancreatic digest of casein and its
use yielded 23.4 mg L-1, whereas the provision of casamino acids, which is
obtained by acidic hydrolysis of casein yielded only 13.7 mg L-1. In contrast,
the highest myxopyronin A concentration was obtained by the use of meat
peptone, with a ﬁnal concentration of 45.7 mg L-1. The two non-animal pep-
tones yeast extract (a yeast autolysate) and soy peptone (enzymatic digest of
soy ﬂour) yielded ﬁnal product concentrations of 24.5 mg L-1 and 15.7 mg L-1,
respectively.
In parallel, a Design of Experiment (DoE) study was conducted aiming at
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the screening of cultivation parameters with regards to their inﬂuence on the
product concentration. The investigated parameters were cultivation tem-
perature, pH, DO (dissolved oxygen) concentration and air ﬂow rate. As
experimental setup, a fractional factorial design was chosen which resulted
in eight fermentation runs with diﬀerent parameter combinations plus three
center point runs. The parameter settings for each fermentation are shown
in Table 3.2. The temperature range was chosen to be from 25-35 ◦C, the pH
range from 6.5 to 8.5, the DO setpoint range from 5-40 % and the range of
the air ﬂow rate from 0.01 to 0.1 vvm. The center points, represented by the
runs N9-N11, are the mean values of the extreme values of each investigated
parameter. In Figure 3.6, the maximum myxopyronin A concentrations for
the 11 DoE fermentation runs are presented.
Table 3.2: Parameter settings for the 11 DoE fermentation runs for the production of myxopyronin A.
Run No. Temperature
[◦C]
pH setpoint
[-]
DO setpoint
[%]
Air ﬂow rate
[vvm]
N1 25 6.5 5 0.01
N2 35 6.5 5 0.1
N3 25 8.5 5 0.1
N4 35 8.5 5 0.01
N5 25 6.5 40 0.1
N6 35 6.5 40 0.01
N7 25 8.5 40 0.01
N8 35 8.5 40 0.1
N9 30 7.5 22.5 0.055
N10 30 7.5 22.5 0.055
N11 30 7.5 22.5 0.055
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Figure 3.6: Maximum myxopyronin A concentrations of the DoE fermentation runs. The runs N2,
N4, N6 and N8 did not yield any product. The error bar represents the standard deviation
of the three center point runs N9-N11.
The center point runs N9-N11 are clearly in the same product concentration
range with a mean value of 16.9 ± 2.8 mg L-1 myxopyronin A after 91.3 h at
which time point the highest product concentrations of all three runs could be
measured. During the further course of the fermentation, the concentrations
decreased, probably due to instability of the product. The runs at 25 ◦C
cultivation temperature yielded between 37.4 mg L-1 (N7) and 61.6 mg L-1
(N5) myxopyronin A. The product formation kinetics of runs N3 and N7 were
comparable to those of the center point runs, whereas those of runs N1 and
N5 were much slower with maximum product concentrations after 210.5 h and
243.6 h, respectively. This fact lets one assume that the process parameters
other than the temperature have an inﬂuence on the product formation or
maximum concentration. However, when looking at the DoE model that was
created by the software, it can be seen that the temperature is the only factor
that has a signiﬁcant inﬂuence on the product concentration (Figure 3.7).
The inﬂuence of the other factors is smaller than the standard deviation
calculated from the center point runs and is therefore not signiﬁcant. With
temperature as the only signiﬁcant factor, the model created has a coeﬃcient
of determination of R2=0.91.
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Figure 3.7: Inﬂuence of the diﬀerent cultivation parameters on the myxopyronin A concentration
according to the DoE model. The error bars represent the standard deviation of the
three center point runs.
As the DoE showed a positive inﬂuence of lower temperatures on the myxo-
pyronin A concentration, fermentations with the standard medium and the
standard parameters at diﬀerent temperatures were conducted. The results
are shown in Figure 3.8.
The outcome of this experiment strengthens the results of the DoE runs.
The highest product concentration (86.9 mg L-1) could be achieved at a
cultivation temperature of 20 ◦C, followed by a maximum concentration of
68.1 mg L-1 at 22 ◦C, 54.0 mg L-1 at 25 ◦C and 36.6 mg L-1 at 28 ◦C. For
online monitoring of the growth of a culture, the carbon dioxide transfer rate
(CTR) can be used. Unfortunately, the CTR in these parallel cultivations
was only recorded for 120 h due to a technical defect. For further observation
of the cultures' growth over the whole cultivation time, the amount of added
sulfuric acid was recorded (Figure 3.8C). This can also be correlated to the
growth because the catabolism of amino acid results in the accumulation of
ammonia which is exported by the bacteria. In order to keep the pH at the
given set point, sulfuric acid is added. Thus, the more peptides are catabo-
lized, the more ammonia is built and the more sulfuric acid is added to the
culture. When comparing growth kinetics with product formation kinetics,
a correlation between growth and product formation seems likely.
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Figure 3.8: Course of A the myxopyronin A concentration, B the carbon dioxide transfer rate (CTR)
and C added sulfuric acid over the cultivation time for bioreactor fermentations with
standard medium at diﬀerent temperatures.
To combine the results of the media screen and those of the cultivations at
diﬀerent temperatures, bioreactor fermentations with meat peptone medium,
the substrate with which the highest product concentrations could be ob-
tained in the media screening, were ensued. As the product formation in the
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cultivation at 20 ◦C was much slower than this at 22 ◦C (stationary phase
reached after 166 h compared to 261 h at 20 ◦C), cultivations with the meat
peptone medium were only done at 22 ◦C, 25 ◦C, 28 ◦C and 30 ◦C. The
results are shown in Figure 3.9.
Figure 3.9: Course of A the myxopyronin A concentration, B the carbon dioxide transfer rates
(CTR) and C the added volume of sulfuric acid over the cultivation time for bioreactor
fermentations with meat peptone medium at diﬀerent temperatures.
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In accordance to the cultivations done with the standard medium, tempera-
ture also has a negative inﬂuence on the myxopyronin A concentrations when
using the meat peptone medium. The highest concentration was reached at
22 ◦C (93.7 mg L-1), whereas at 25 ◦C, 28 ◦C and 30 ◦C maximum con-
centrations of 71.0 mg L-1, 46.0 mg L-1 and 47.9 mg L-1, respectively, could
be achieved. Notably, the product concentrations as well as the product
formation kinetics were similar at 28 ◦C and 30 ◦C with the meat peptone
medium, which could not be observed with the standard medium. In general,
the product titers in meat peptone medium were higher at all temperatures
than the cultivations done with the standard medium. In comparison to the
starting conditions (30 ◦C and skim milk medium) the product concentration
could be increased 5.6-fold when using meat peptone medium and a cultiva-
tion temperature of 22 ◦C.
When looking at the CTR, the growth of the culture again correlated with
the product formation. The latter started for all cultivations in the late ex-
ponential growth phase. In the cultures with 28 ◦C and 30 ◦C cultivation
temperature, product formation soon stagnated whereas at 22 ◦C and 25 ◦C
the myxopyronin A concentration still increased during the stationary growth
phase. The oscillation of the CTR is caused by the fact that whenever the cul-
ture becomes more acidic, carbon dioxide that was formerly dissolved in the
medium is released. When the pH is regulated by adding potassium hydrox-
ide more carbon dioxide can be dissolved again. Therefore, these ﬂuctuations
do not represent the true carbon dioxide emission rate (CER), a problem that
has been addressed by several publications before [219, 220, 218]. The added
volume of sulfuric acid also correlated with the CTR. Notably, the CTR does
not diﬀer signiﬁcantly between the fermentations in the standard (skim milk
powder) and meat peptone medium, whereas the added volume of sulfuric
acid is about factor two higher in the meat peptone medium. Thus, this
parameter can only be compared for cultivations in the same medium.
In an eﬀort to increase the product concentration further, the possible bottle-
neck of building block supply was addressed. The eastern chain of myxopy-
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ronin A contains one glycine and three malonyl-CoAs whereas the western
chain is made up out of acetyl-CoA as a starter unit, elongated by three
malonyl-CoAs [138]. Malonyl-CoA is synthesized from acetate via acetyl-
CoA [161]. Thus, acetate supply was increased by using acetic acid for
pH correction instead of sulfuric acid. In a second fermentation, the ef-
fect of kanamycin on the product formation was explored. Kanamycin was
thus far used to keep up the selective pressure to ensure the incorporation
of the heterologous gene cluster. Furthermore, it could be deduced from the
experiments presented in Figure 3.9 that myxopyronin A formation corre-
lated with the growth of the culture. In order to prolong the growth phase
and correspondingly the time of product formation, a fed-batch fermentation
was performed. The feed consisted of meat peptone medium with 3-times
concentrated meat peptone and was started 96 h after inoculation. It was
kept at constant speed for another 96 h. The product concentrations, CTRs
and added acid volume of these fermentations are presented in Figure 3.10
as well as those of the standard fermentation at 22 ◦C for comparison.
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Figure 3.10: A Myxopyronin A concentrations, B carbon dioxide transfer rates (CTR) and C added
acid volume over the course of the cultivation time for the standard batch at 22 ◦C, a
fed-batch (with sulfuric acid for pH correction) and the fermentations using acetic acid
for pH correction and without kanamycin (also at 22 ◦C).
When looking at the myxopyronin A concentration, it can be deduced that
using acetic acid for pH correction only has a slight positive eﬀect that re-
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sults in a maximum concentration of 101.1 mg L-1. Nevertheless, it seemed
to be beneﬁcial for the bacterial growth as the CTR did not decline as fast
as the one of the standard fermentation. For this reason, acetic acid was
also used when testing the inﬂuence of kanamycin on the product formation.
The CTRs of the fermentations with and without kanamycin are similar, but
the product concentration is signiﬁcantly higher without kanamycin with a
maximum myxopyronin A concentration of 142.2 mg L-1. The volume of
added acid was also higher in the cultivations with acetic acid compared to
the standard batch. The fed-batch fermentation resulted in only slightly in-
creased product concentrations (109.0 mg L-1) although the CTR was higher
than this of the standard batch. The volume of added acid on the other hand
was 24 % lower.
In general, the product concentration could be increased from 16.9 mg L-1
(skim milk medium at 30 ◦C with sulfuric acid and kanamycin) to
142.2 mg L-1 (meat peptone medium at 22 ◦C with acetic acid without
kanamycin) which accounts for an almost tenfold increase only through ad-
justment of media components and cultivation parameters.
3.2.2 Heterologous Production of Vioprolides
Natural product formation of myxobacteria largely depends on the choice of
substrate in nutritional media because of their complex nutritional require-
ments. Naturally, Myxococcus xanthus feeds on other bacteria, a complexity
of nutrients which is hard to mimick in cultivation media. In an attempt
to ﬁnd a suitable substrate, diﬀerent complex carbon-nitrogen-sources (CN-
sources) were tested for their ability to promote vioprolide production. The
CN-sources used were skim milk powder, casein, casitone, meat peptone,
yeast extract and soy peptone, media components frequently used for culti-
vation of M. xanthus [191, 193]. The medium containing 20 g L-1 skim milk
was set as a basis. Via HPLC measurements, it could be deduced that skim
milk powder consists of 30 % lactose (data not shown). Thus, in the media
containing the other CN-sources, the 20 g L-1 skim milk powder was substi-
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tuted by 14 g L-1 CN-source and 6 g L-1 lactose to avoid any bias through
omitting the sugar. The results of the shake ﬂask experiment for castione,
yeast extract, meat peptone and soy peptone can be seen in Figure 3.11.
It was not possible to determine the product concentrations for skim milk
powder and casein as a substrate, because the product peaks were overlaid
by media component peaks.
Figure 3.11: Concentrations of the diﬀerent vioprolide derivatives over the course of the shake ﬂask
cultivation for A casitone, B yeast extract, C meat peptone and D soy peptone. Data
points are the mean value of three shake ﬂasks, the error bars represent the standard
deviation.
As can be seen, vioprolides A and B are determined together as it was impos-
sible to separate the two peaks with the analytical HPLC columns available.
Schummer et al. could separate the two derivatives only with reversed-phase
and subsequent normal-phase chromatography [77]. As this procedure was
too time-consuming considering the number of samples, the two peaks were
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detected together.
When comparing the diﬀerent CN-sources, it can be seen that product for-
mation started at 48 h with maximum concentrations between 4.4 mg L-1 and
19.9 mg L-1 with yeast extract yielding the highest concentration of viopro-
lides A+B and meat peptone of vioprolide C. Meat peptone was furthermore
the only substrate where vioprolide C was the most abundant derivative.
Based on these results, bioreactor cultivations were conducted to verify the
product formation, the results of which are presented in Figure 3.12.
Figure 3.12: Concentrations of the diﬀerent vioprolide derivatives over the course of the bioreactor
cultivation for A meat peptone, B yeast extract, C casitone and D soy peptone. The
gray line represents the carbon dioxide transfer rate (CTR).
The product concentrations for the bioreactor cultivations were higher than
in the shake ﬂask experiments, with concentrations of up to 128.4 mg L-1 for
vioprolides A+B (in yeast extract). These high titers were especially reached
when using meat peptone and yeast extract. But these two substrates diﬀered
in the most abundant derivative (vioprolide C for meat peptone, vioprolides
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A+B for yeast extract) and in the growth characteristics of the culture which
can be deduced by the carbon dioxide transfer rate (CTR). For meat pep-
tone, the highest CTR value (3.4 mM h-1) was reached after 59.5 h with
a steady decline afterwards. After 144 h, only minimal respiratory activity
could be monitored. For yeast extract, the highest CTR value of 2.8 mM h-1
was lower than when using meat peptone, but it was already reached after
45.5 h.
Furthermore, the decline of the CTR was slower with minimal respiratory
activity detected after 192 h. This shows that meat peptone was metab-
olized more rapidly, but was already depleted after 59.5 h, whereas yeast
extract was metabolized more slowly. The oscillation of the CTR is caused
by the fact that whenever the culture becomes more acidic, carbon dioxide
that was formerly dissolved in the medium is released. When the pH is reg-
ulated by adding potassium hydroxide more carbon dioxide can be dissolved
again. Therefore, these ﬂuctuations do not represent the true carbon dioxide
emission rate (CER), a problem that has been addressed by several publica-
tions before [218, 219, 220]. The formation of vioprolides started when the
CTR is already declining, in the so-called stationary phase, which is typical
for secondary metabolites [221]. Since casitone and soy peptone yielded only
maximum concentrations of 67.0 mg L-1 and 48.0 mg L-1 vioprolides A+B,
respectively, they were not considered for further experiments.
In a consecutive attempt to reach the goal of improved vioprolide yields,
shake ﬂask cultivations were performed where amino acids that are viopro-
lide buliding blocks were fed to cultures growing in yeast extract medium.
The results were striking (Figure 3.13). As in the previous cultivations with
yeast extract medium, vioprolides A+B were the most abundant derivatives.
Interestingly, the concentration of vioprolides A+B could be enhanced even
more by adding DL-pipecolic acid to the culture (43.0 mg L-1 compared to
30.9 mg L-1 for the control). On the other hand, the concentration was
lower when L-proline was added (20.8 mg L-1). The contrary can be seen
when looking at vioprolides C and D. Here, the product concentrations were
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higher when L-proline was added with 13.4 mg L-1 and 14.1 mg L-1 for vio-
prolides C and D, respectively, than for the control (11.6 mg L-1 vioprolide
C and 7.6 mg L-1 vioprolide D). The addition of DL-pipecolic acid led to de-
creased concentrations of vioprolide C and D, with 3.3 mg L-1 and 3.0 mg L-1,
respectively.
Figure 3.13: Concentrations of A vioprolides A+B, B vioprolide C and C vioprolide D after addition
of diﬀerent amino acids to the shake ﬂask cultures growing in yeast extract medium.
The amino acids were added after 48 h. Data points are the mean value of three shake
ﬂasks, the error bars represent the standard deviation.
Bioreactor cultivations were performed in order to verify the results obtained
from the amino acid feeding experiments. Either L-proline or DL-pipecolic
acid was added to cultures in meat petone and yeast extract medium. Strik-
ingly, a maximum concentration of 141.4 mg L-1 (Figure 3.14D) was reached
which is only 13.0 mg L-1 higher than this obtained without any amino acid
supplementation (Fig. 3.12B). In the shake ﬂask experiment, the titer of
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vioprolides A+B could be increased 1.4-fold through the addition of DL-
pipecolic acid (Fig. 3.13A). Although the concentration of vioprolides A+B
could not be enhanced, the formation of the other two derivatives could ap-
parently be suppressed in this experiment. Only 24.6 mg L-1 vioprolide C and
14.3 mg L-1 vioprolide D could be detected in comparison to 53.2 mg L-1 and
19.2 mg L-1 in the fermentation without any amino acids. The addition of L-
proline to the culture in yeast extract medium caused a shift from vioprolidea
A+B to vioprolide C being the most abundant derivatives. The maximum
concentration of vioprolide C was 128.8 mg L-1 (Fig. 3.14C) which accounted
for a 2.4-fold increase compared to plain yeast extract medium (53.2 mg L-1)
(Fig. 3.12B). Furthermore, the yield of vioprolide D could be enhanced as
well from 19.2 mg L-1 to 36.4 mg L-1.
The results obtained from adding DL-pipecolic acid or L-proline to cultures
with meat peptone medium completed the picture. Through supplementa-
tion of L-proline, the concentration of vioprolide C could be increased from
110.5 mg L-1 (Fig. 3.12A) to 182.2 mg L-1 (Fig. 3.14A). The vioprolide D
titer was also positively aﬀected by the addition of L-proline (50.8 mg L-1
compared to 40.5 mg L-1). Even more striking is the result of the supplemen-
tation of DL-pipecolic acid to the culture in meat peptone medium. Here, the
vioprolides A+B concentration could be increased 6.2-fold from 64.5 mg L-1
(Fig. 3.12A) to 400.0 mg L-1 (Fig. 3.14B).
Subsequently, bioreactor cultivations with combined supplementation of L-
proline and DL-pipecolic acid to meat peptone and yeast extract medium
were performed. This led to the highest concentration of vioprolide C ob-
tained in yeast extract medium with a maximum of 179.8 mg L-1 (Fig. 3.15B).
Although DL-pipecolic acid was fed as well, the titer of vioprolide A+B was
lower (71.2 mg L-1) than when feeding only L-proline (116.6 mg L-1) (Fig.
3.14C). The vioprolide D concentrations stayed the same with a maximum
concentration of 34.4 mg L-1 compared to 36.4 mg L-1 when only L-proline
was fed.
The combined supplementation of L-proline and DL-pipecolic acid to the cul-
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Figure 3.14: Concentrations of the diﬀerent vioprolide derivatives over the course of the bioreactor
cultivation for A meat peptone with L-proline, B meat peptone with DL-pipecolic acid,
C yeast extract with L-proline and D yeast extract with DL-pipecolic acid. The gray
line represents the carbon dioxide transfer rate (CTR). The amino acids were added
after 48 h.
ture grown in meat peptone medium did not have any positive eﬀect on the
vioprolide yield. The derivatives A+B were the most abundant ones with a
maximum concentration of 168.0 mg L-1, as through supplementation with
solely DL-pipecolic acid, but without reaching its titer (Fig. 3.15A). The
concentrations of vioprolides C and D were at 52.0 mg L-1 and 41.5 mg L-1,
respectively.
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Figure 3.15: Concentrations of the diﬀerent vioprolide derivatives over the course of the bioreactor
cultivation for A meat peptone with L-proline and DL-pipecolic acid and B yeast extract
with L-proline and DL-pipecolic acid. The gray line represents the carbon dioxide
transfer rate (CTR). The amino acids were added after 48 h.
4 Discussion
4.1 Production of Elansolids with Chitinophaga sancti Fx7914
Elansolids are interesting candidates for drug development, but chemical
synthesis is to date only available for elansolid B1 [222] and not feasible
in multi-gram scale. Therefore, provision of substantial amounts of elan-
solids to enable further semi-synthetic drug development is only achievable
by biotechnological means. The chosen strategy was two-fold: Our ﬁrst ap-
proach aimed towards the production of elansolid A2. This is an ideal start-
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ing point for chemical optimization of the molecule where the ring-structure
shall be retained whereas our second approach aimed towards the biotechno-
logical production of a linearized derivative by adding a nucleophile (in our
case anthranilic acid) to the culture, thereby preventing the accumulation of
undesired side products.
In the batch fermentation, we could show that sucrose was cleaved and the
monosaccharides were metabolized separately, with glucose as the preferred
substrate, yielding 18.9 mg L-1 elansolid A2. The cleavage of sucrose might be
carried out by extracellular invertases. These ﬁndings are well in accordance
with publications showing that Chitinophaga pinensis, a close relative of C.
sancti, possesses a variety of carbohydrate-active enzymes (CAZymes) for the
degradation of carbohydrates, among them invertase [87, 223, 224, 225]. The
preferred usage of glucose over other carbon sources has been well observed
in diﬀerent types of organisms under the term carbon catabolite repression
[226, 227].
To increase elansolid A2 production, a fed-batch fermentation was applied.
Sucrose was chosen as the carbon source in the basal medium whereas glu-
cose was provided in the feed solution as it was shown to enable rapid
growth. Hence, the product concentration could be increased almost 3-fold
from 18.8 mg L-1 in the batch fermentation to 55.3 mg L-1 in the fed-batch
fermentation. The fed-batch fermentation with glucose as sole carbon source
resulted in only 31.8 mg L-1 elansolid A2 but 223.1 mg L-1 elansolid C1.
Elansolid C1 is generated when anthranilic acid acts as a nucleophile that
attacks the quinone methide ring of elansolid A3 [120]. Since in this process
anthranilic acid must be produced by the organism itself presumably as a
precursor for tryptophan biosynthesis, accumulation of anthranilic acid and
its subsequent side reactions with elansolid A3 could possibly be prevented
by feeding tryptophan and thereby exploiting a possible feedback inhibition
of the trp-operon [228]. This will be subject of further research for pro-
cess improvement. Furthermore, the feeding rates need to be adapted to
avoid glucose accumulation during the feeding phase. In two of the fed-batch
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fermentations, glucose accumulated to ﬁnal concentrations of 37.3 mg L-1
and 77.5 mg L-1 and although growth and product formation did not seem
to be aﬀected by a potential overﬂow metabolism, the accumulation of not
metabolized substrates reduces process proﬁtability and should therefore be
minimized in future experiments.
To prove the concept of precursor-directed biosynthesis of novel elansolid
derivatives that harbor several interesting advantages, anthranilic acid was
provided in the medium as a precursor in another fermentation. Here, an
elansolid C1 concentration of 257.5 mg L-1 has been obtained. This yield
is equivalent to a 36-fold increase in product concentration compared to
7.1 mg L-1 which could be achieved by fermentation so far.
The precursor-directed biosynthesis during fermentation when providing an-
thranilic acid allowed the formation of the desired product in high amounts
whereas formation of other elansolid derivatives occurred only in minor con-
centrations (85 % elansolid C1, Figure 3.4C). Accordingly, this procedure
should be further investigated as basis for the creation of diﬀerent novel
elansolid derivatives, since the semi-synthetic approach within crude extracts
proposed by Steinmetz et al. [120] is accompanied by a considerable loss of
product.
The precursor-directed elansolid production is of special interest since al-
though the absolute amount of elansolid A2 was increased considerably com-
paring absolute product titers of batch fermentation and fed-batch fermen-
tation with sucrose, its share of the overall elansolid yield was similar with
14 % in the batch (Figure 3.1c) and 15 % in the fed-batch process (Figure
3.2c). The presence of these side-products increases the workload for puriﬁ-
cation of elansolid A2. Subsequently, after chromatographic puriﬁcation of
elansolid A2, which is additionally hampered by the stability of the molecule,
the compound must be chemically converted into the desired product. This
can only be accomplished with considerable losses at this time [119].
In this light, the precursor-directed synthesis of new elansolid derivatives di-
rectly during the fermentation might provide a promising tool in the search
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for novel antibiotics, especially since conversion into the more stable non-
cyclic derivative elansolid C1 is accompanied by only a minor loss of activity
even when observing Gram-negative permeabilized cells. Thus, one focus of
medicinal chemistry approaches could be the structure modiﬁcation towards
increased cell wall penetration.
4.2 Heterologous Production of Myxobacterial Products with
Myxococcus xanthus DK1622
4.2.1 Heterologous Production of Myxopyronin A
Complex media components are essential for the growth of M. xanthus
DK1622, as they provide carbon and nitrogen in form of proteins and pep-
tides. Skim milk powder consists of approximately 36 % proteins, of which
casein makes up about 80 % [229]. Consequently, the composition of the
skim milk (SM) and casein (CS) media were similar in terms of protein con-
tent. Since the myxopyronin A concentrations were also similar in both
media, the substitution of skim milk with lactose and casein seemed to have
no inﬂuence. Slightly lower product concentrations could be obtained with
casitone, a pancreatic digest of casein, which contains peptides in diﬀerent
size (up to 5,000 Da) [230]. Casamino acids are acidic hydrolysates of casein,
which results in single amino acids and small peptides (90 % < 250 Da) [231].
When comparing the product titer and the growth curve of the diﬀerent milk
protein media, it can be deduced that the more the proteins are broken up
into smaller peptides or single amino acids the lower the product concentra-
tion. This phenomenon has already been observed before [191]. Yeast extract
contains peptides with higher molecular weight (up to 5,000 Da), but also
contains carbohydrates (approx. 16 %). The same holds true for soy peptone
(approx. 30 % carbohydrates) [232]. As carbohydrates cannot be metabo-
lized by M. xanthus, the overall nutritional value is lower than this of pure
protein hydrolysates. The highest myxopyronin A concentration however
was observed with the meat peptone medium. This can be explained by the
presence of peptides with higher molecular weight (up to 10,000 Da) [233].
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Besides media composition, process parameters can have an inﬂuence on
the growth of the culture and concomitantly on the product concentration.
Therefore, the inﬂuence of temperature, pH, DO setpoint and air ﬂow rate
was investigated. The pH can have an inﬂuence on the growth of the organ-
ism as well as the stability of the product in the culture medium. Hüttel
and Müller could also show that the product proﬁle of Chondromyces cro-
catus, another myxobacterium, changed depending on O2 and CO2 levels
([197]. The level of dissolved CO2 in a medium is smaller at higher air ﬂow
rates because of the faster gas exchange. Diﬀerent product proﬁles could
also be observed for the heterologous expression of epothilones in M. xanthus
DZ1 [196]. However, in this study, solely the temperature had a signiﬁcant
inﬂuence on the myxopyronin A concentration. In case of the soraphens,
temperatures over 30 ◦C drastically decreased the product concentrations as
also observed in this study [56]. Several studies have also shown that a lower
temperature aids in the correct folding of the biosynthetic PKS machinery
when heterologously expressed in E. coli [161, 163, 234]. Another reason
could be a redistribution of nutritional resources to secondary metabolite
production when growth is forced to be slowed down due to lower cultivation
temperatures. The Design of Experiments setup helped to rule out any inter-
actions of two factors that would not have been recognized when employing
the one-factor-at-a-time approach. The beneﬁts of a statistical approach on
all ﬁelds of process optimization are also summarized in an excellent review
[200].
After exploring the growth and product formation kinetics at diﬀerent tem-
peratures, 22 ◦C was chosen as cultivation temperature for further exper-
iments. Here, the addition of acetic acid for pH correction showed to be
beneﬁcial for the growth of the culture resulting in a slightly higher CTR
combined with a slower decline at the end of the fermentation. This could
be explained by the fact that M. xanthus is able to use some organic acids,
among them acetate, as substrate [192, 235].
The fed-batch fermentation did not yield signiﬁcantly higher product con-
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centrations than the standard batch, although the CTR was increased. One
reason could be that the concentration of meat peptone was too high in this
regard that its catabolism resulted in an accumulation of ammonia that was
inhibitory for the organism. Normally, this is also reﬂected in an increased
addition of acid. In this case, this logic was subverted by the addition of
the feed that was slightly acidic after autoclaving. Future experiments will
involve optimization of feed composition and proﬁle to be able to increase
the ﬁnal product concentrations.
Omitting kanamycin during cultivation increased the myxopyronin A con-
centration by 40 mg L-1. Although chromosomal integration of gene clusters
is regarded as stable, kanamycin was used because of the ability to study the
behavior of the organism without the possibility of losing the gene cluster.
But the integration seemed to be stable as even more product was built. This
could be due to the lower metabolic burden, because resistance enzymes did
not be expressed if no kanamycin is present in the culture.
In general, it could be shown that heterologous expression of myxobacte-
rial natural products in the closely related host Myxococcus xanthus DK1622
can be a mean to increase the product supply for further research. In this
study, the production of one of two myxobacterial α-pyrone antibiotics was
investigated. As the biosynthetic gene cluster of the other one, namely coral-
lopyronin, has also been integrated into M. xanthus DK1622 recently [214],
it will be interesting to see if the results obtained for myxopyronin can be
applied to corallopyronin production as well. This could be a major step on
the way of promotingM. xanthus DK1622 as a high-titer expression platform
for myxobacterial natural products.
4.2.2 Heterologous Production of Vioprolides
The goal of this study was to ﬁnd a suitable production process for the vio-
prolides originally produced by Cystobacter violaceus Cb vi35. As Yan et al.
established, the production level was signiﬁcantly higher in the heterologous
producer M. xanthus ::Ptn5-vio than in the original producer [215]. However,
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the titers that could be reached in the ﬁrst shake ﬂask experiments were only
a total of 35.0 mg L-1 vioprolides in yeast extract medium and a total of
24.8 mg L-1 in meat peptone medium (Figure 4.1).
Figure 4.1: Summed concentrations of all vioprolide derivatives for the experiments carried out in A
yeast extract medium and B meat peptone medium. SF=shake ﬂask, BR=bioreactor,
pro=L-proline, pip=DL-pipecolic acid.
An increase of the product titers could be achieved through bioreactor cul-
tivations. Here, concentrations of 200.8 mg L-1 vioprolides A-D (for yeast
extract medium) and 215.5 mg L-1 (for meat peptone medium) could be
reached. This diﬀerence originates most likely from the cultivation environ-
ment that is more controlled in the bioreactor cultivations than in the shake
ﬂask experiments.
One parameter that is regulated in bioreactor cultivations but not in shake
ﬂaks experiments is the pH. As can be seen in Figure 4.2, the pH increased
despite the addition of HEPES to the medium from 7.2 at the beginning of
the cultivation to a value of 8.6 for meat peptone medium (after 210.5 h) and
8.7 for yeast extract medium (after 142.3 h).
The pH would have also increased in the bioreactor cultivations, if it had not
been kept at a constant level through the addition of sulfuric acid (Figure
4.3). The increased addition of sulfuric acid to the cultivation in meat pep-
tone medium (133 mL) can be correlated to the higher CTR (Fig. 3.12A)
compared to the cultivation in yeast extract medium (Fig. 3.12B). This fact
can be explained by a somehow higher nutritional value of the meat peptone
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Figure 4.2: Course of the pH over the cultivation time for shake ﬂask experiments carried out in
meat peptone and yeast extract medium. Data points are the mean value of three shake
ﬂasks, the error bars represent the standard deviation.
medium that allowed a faster metabolism and therefore faster growth. The
end product of amino acid metabolism (the components of peptones) is am-
monia [193, 235]. It is excreted which ultimately leads to an increase in the
pH that in turn is counteracted by the addition of sulfuric acid. The more
amino acids are metabolized the more ammonia is excreted and the more
sulfuric acid needs to be added to keep the pH constant.
In order to test whether the higher product concentrations in the bioreactor
cultivations could be attributed to the constant pH, a bioreactor cultivation
with HEPES but without the addition of sulfuric acid was performed (Fig.
4.4). As can be seen, the pH also increased from 7.5 to a value of 8.8 at the
end of the cultivation (Fig. 4.4B). The CTR is similar between the cultiva-
tions with and without the addition of HEPES. With a total of 64.0 mg L-1
vioprolides the concentrations lay between that of the shake ﬂask experiments
and the bioreactor cultivations. Therefore, the constant pH in the bioreactor
cultivations possibly has a positive inﬂuence on the product titer. One expla-
nation could be a decreased stability of the vioprolides at high pH. But there
are also other cultivation parameters that cannot be controlled in shake ﬂask
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Figure 4.3: Course of the pH and the added volume of sulfuric acid over the cultivation time for
bioreactor cultivations performed in meat peptone and yeast extract medium. YE=yeast
extract, MP=meat peptone.
experiments which could have an inﬂuence on the product titer, like the oxy-
gen supply. As Hüttel & Müller could show, the secondary metabolite proﬁle
of a Chondromyces strain varied between bioreactor cultivations with diﬀer-
ent DO setpoints [197]. More studies have to be conducted in order to ﬁnd
the reason for the increased vioprolide production in bioreactor cultivations,
also with the prospect of optimizing these even further.
One observation that could be made in the shake ﬂask experiments was the
control of the derivative distribution through the supplementation of speciﬁc
amino acids. These results could also be veriﬁed in the bioreactor cultivations
(Fig. 4.1). Addition of DL-pipecolic acid led to increased titers of vioprolides
A+B in yeast extract as well as in meat peptone medium. L-pipecolic acid
is a six-ring building block of vioprolides A and B and a non-proteinogenic
amino acid. Although the racemic mixture was used, it can be assumed that
only the L-isomer was incorporated as previously observed [170, 171]. This
could be investigated further by feeding only the pure isomers. This would
also increase the vioprolide yield relating to the amount of used pipecolic
acid. As racemically pure substance is quite expensive, another way of sup-
plying L-pipecolic acid could be the feeding of L-lysine. In bacteria, pipecolic
acid was found to be generated from lysine through diﬀerent reactions [236].
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Figure 4.4: A Concentrations of the diﬀerent vioprolide derivatives and B the course of the pH and
the CTR over the course of the bioreactor cultivation in meat peptone medium with
HEPES.
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Chai et al. could elucidate that a lysine cylcodeaminase catalyzes this re-
action step in the myxobacterium Angiococccus disciformis An d48, where
piepcolic acid serves as a starter unit for tubulysin biosynthesis [170]. This
enzyme is also involved in provision of pipecolic acid for other PK/NRP-based
natural products [237, 238]. If, on the other hand, this cyclodeamination step
is the bottle neck in pipecolic acid supply, the feeding of L-lysine would not
enhance the titers of vioprolide A+B. This conclusion was made after feeding
DL-piecolic acid to a culture of a heterologous Pseudomonas putida strain
producing tubulysin. The supplementation also led to substantial increases
in pre-tubulysin A [171].
Vioprolides A and C are one of the few examples of natural products
containing an azetidine ring. A few plant-derived compounds like mug-
ineic acid [239], calydaphninone [240], gelsemoxonine [241] and azetidine-2-
carboxylic acid are known of which biosynthesis studies showed that azetidine
is formed from 2,4-diaminobutyric acid which itself derives from S-adenosyl-
L-methionine or homoserine [242]. Azetidine-2-carboxylic acid which only
lacks the methyl group at C4 in comparison to 4-Maz was discovered in
lilies, poincianas and sugar beet where it has the eﬀect of deterring the
growth of competing vegetation and poisoning predators [243]. The toxi-
city of azetidine-2-carboxylic acid has been reported for a variety of species,
including poultry, rodents and humans [244, 245]. Accordingly, the 4-Maz
could be the origin of the cytotoxic activity observed for the vioprolides. This
could be a promising starting point for further SAR studies. Apart from the
vioprolides there is only one group of bacterial metabolites containing an
azetidine ring, namely the polyoxins produced by Streptomyces cacaoi [246].
Here, feeding studies [247, 248] as well as in silico genome analysis [249] re-
vealed the formation of the polyoximic acid from isoleucin, which itself can be
generated from methionine, threonine and glutamate. From these four amino
acids, only L-threonine was fed to to the culture in this study, which did not
result in elevated titers of either vioprolides A+B or C (the 4-Maz is incor-
porated in vioprolides A and C) (Fig. 3.13A+B). Additional experiments
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feeding isoleucine, methionine and glutamate will have to be conducted to
be able to investigate any eﬀects on the product concentration.
The feeding of L-proline led to increased product concentrations of viopro-
lides C and D in both media (Fig. 4.1). Interestingly, the titer of vioprolide C
could be increased 1.6-fold (in meat peptone medium) and 2.4-fold (in yeast
extract medium), whereas the concentration of vioprolide D was only 25 %
and 90 % higher, respectively. This is interesting because vioprolide D con-
sists of two L-proline moieties, vioprolide C of only one (Fig. 1.7). Vioprolide
B also contains one L-proline, but the concentration of vioprolides A+B in-
creased only in meat peptone medium when L-proline was fed to the culture
by 52 %. In yeast extract medium, the concentration of vioprolides A+B
even decreased after addition of L-proline. Taking these facts into account,
it seems as if the amino acid supplementation aﬀects the building blocks at
one position (L-pipecolic acid for vioprolides A+B, L-proline for vioprolides
C+D) more than the ones incorporated at another position (4-Maz for vio-
prolides A+C, L-proline for vioprolides B+D). As 4-Maz has not been fed so
far, this statement is purely hypothetical. To investigate the fate of the sup-
plemented amino acids in general, it could be useful to add isotope-labeled
amino acids [250]. This method helps to elucidate whether these amino acids
are used for general cellular protein synthesis or for the biosynthesis of sec-
ondary metabolites. For the heterologous production of myxochromides in
Pseudomonas putida::CMch37a it could be shown that the production was
substantially enhanced through feeding of the precursor amino acids. Fur-
thermore, the study revealed that the added amino acids are to a large extent
directly incorporated in the product, due to an increased intracellular avail-
ability [251]. The observation that the distribution of derivatives generally
diﬀered between yeast extract and meat peptone medium could also be at-
tributed to the varying supply of diﬀerent amino acids in these two media
components.
In this study, it could be shown that the derivative distribution of viopro-
lides heterologously produced by M. xanthus DK1622 can be controlled by
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the supplementation of speciﬁc precursor amino acids. As some of the viopro-
lides are interesting candidates for drug-development, this method presents a
simple way of producing the desired compounds in a multi-gram scale. But,
as pointed out, more experiments are necessary to understand the nutritional
behavior ofM. xanthus DK1622 as well as the vioprolide biosynthesis in order
to being able to optimize this process even further.
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5 General Discussion and Outlook
In the last three decades, the number of new anti-infective drugs on the
market has decreased drastically compared to the period of 1940-1980. One
reason is the fact that pharmaceutical companies have resigned from natural
product research because the number of new promising compounds was too
low compared to the time and eﬀort needed. With the beginning of the
1990s combinatorial chemistry was thought to ﬁll the gap but eﬀectively only
two drugs discovered by these means have been introduced to the market.
To overcome the current deadlock, so far neglected or underrepresented
species have to be investigated more thoroughly for their potential as sources
of novel anti-infective compounds. The order of Myxococcales consists of
7500 diﬀerent strains that together produce as many as 100 compounds
with diﬀerent core structures and hundreds of derivatives. Most of these
compounds have anti-bacterial, anti-fungal or cytotoxic activities, many
of them having new modes-of-action. Besides the myxobacteria there are
other producers of secondary metabolites living in the soil, like those of the
genera Chitinophaga and Flexibacter. One of the main reasons why these
bacteria have been neglected in the past are the low product titers that
make production of pharmaceuticals economically non-viable. Additionally,
the original producer strains have diverse nutritional requirements and the
products are often unstable. These challenges need to be overcome for
gliding bacteria to become producers of clinically relevant drugs. The three
projects presented in this thesis deal with various aspects of development
and optimization of fermentation processes to increase the accessibility to
these valuable compounds.
The ﬁrst project covered the production of the anti-MRSA compound family
of elansolids by its native producer Chitinophaga sancti Fx7914. Bioreactor
cultivations in complex media, as performed in the past, yielded only the
non-reactive derivatives elansolid B1, B2, C1 and D2. But for medici-
nal chemistry studies investigating the SAR of the elansolids, a reactive
derivative is needed that could be modiﬁed semi-synthetically. The use of a
88
chemically deﬁned medium in combination with compound adsorption with
the adsorber resin XAD16 enabled the production of elansolid A2 with titers
of 55.3 mg L-1. This fact shows that the media composition is a crucial
aspect when optimizing biotechnological processes because it can aﬀect
not only the growth of the microbial strain and the overall yield but the
derivative composition can be inﬂuenced as well. This holds also true for the
second consideration of this project, namely the direct control of derivative
composition by feeding of certain precursors that are incorporated into the
compounds. This approach enabled the production of elansolid C1 through
feeding of anthranilic acid with a concentration of 257.5 mg L-1 and a share
of 85 % in the overall elansolid yield.
This shows the power of biotransformation and biosynthesis. Precursor-
directed chemical synthesis of new elansolid derivatives was shown to
be possible as well but with immensely lower yields. There are already
medicinal chemistry studies underway that investigate the structure activity
relationship of new elansolid derivatives with the aim of improvement of
the physiochemical and pharmacokinetic properties of the molecules. If
compounds with desirable properties are found, the protocol established in
this study could be the basis for precursor-directed biosynthesis approaches
that would allow the production of signiﬁcant amounts of the new com-
pounds necessary for further testing. Through the use of small-scale parallel
cultivation systems the generation of diﬀerent molecules would be possible
as well. If simple precursor-directed biosynthesis did not yield the desired
products, the next step in this direction would be a mutasynthesis approach
where certain biosynthetic pathways were disrupted in the producer strain.
Instead, diﬀerent precursors could be fed that would be incorporated as
building blocks for new elansolid derivatives by C. sancti. The main
requirement for this method is the amenability of the strain for genetic
manipulation which sometimes proofs diﬃcult for gliding bacteria.
The other two projects dealt with the process optimization of the heterolo-
gous production of two diﬀerent types of myxobacterial compound classes
89
with the model strain Myxococcus xanthus DK1622. The concentration of
the α-pyrone antibiotic myxopyronin could be increased from 16.9 mg L-1 to
142.2 mg L-1 mainly due to adaptation of media composition and lowering
of the cultivation temperature. The latter was identiﬁed to be a signiﬁcant
factor with the help of statistical experiment design (DoE). DoE presents a
powerful tool to identify and optimize important factors that inﬂuence the
output variable. In this case, only the ﬁrst step of a DoE round, namely the
identiﬁcation of signiﬁcant factors was carried out, as only the temperature
was identiﬁed to be signiﬁcant and could subsequently be investigated in
a traditional experimental setup. For the DoE approach to uncover its
full potential it is necessary to already have a basic understanding of the
cultivation process to be able to identify errors and outliers. DoE is based
on the mathematical calculation of a model that describes the inﬂuence of
the input factors on the output factors. Since biological processes cannot
always be described with simple correlations based on linear or quadratic
equations, the expertise of the experimenter plays a signiﬁcant role for the
outcome using this statistical approach.
The fact that the product concentrations of vioprolides could be increased
10-fold through bioreactor cultivations compared to shake ﬂask cultivations
is striking. This illustrates the impact of up-scaling on the production
process. The environmental conditions in shake ﬂasks are often not ideal
and cannot be controlled. Bioreactor cultivations on the other hand provide
a controllable environment that can be adjusted to the distinct requirements
and lead to reproducible results. Furthermore, the control of the derivative
composition through feeding of precursors could be demonstrated. This fact
is not be underestimated as most myxobacterial compounds are produced
as a mixture of diﬀerent derivatives of which in many cases only one is
clinically relevant.
The aim of the heterologous expression of these two compound classes was the
investigation of M. xanthus as an expression platform for natural products.
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Figure 5.1: Amount of compound required for each stage of the natural product dicovery process
[252].
As pointed out in chapter 1.5, the strain possesses the properties for expres-
sion and tailoring of PKS- and NRPS-derived compounds. The optimization
of the production processes in the natural host for every product is tedious
and in some cases not very successful. Having an expression platform for
these compounds would facilitate the production and further development.
The two biosynthetic gene clusters were cloned into the same place in the
genome using the same technique to avoid any diﬀerences stemming from the
integration. However, the production kinetics diﬀered immensely between
the two product classes. The α-pyrone myxopyronin A was produced during
the exponential phase with the maximum concentration reached after 48 h
at 30 ◦C cultivation temperature. The stationary phase was reached at the
same time. The growth of M. xanthus DK1622 with the vioprolide biosyn-
thetic gene cluster was generally slower, the stationary phase was reached
after 96 h. Furthermore, the vioprolide production started in the late expo-
nential phase with a maximum concentration reached after 240 h. Both gene
clusters stood under the constitutive tn5 -promoter, so the diﬀerences must
have another origin that needs to be investigated in the future. Further-
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more, the vioprolide concentration could not be increased by lowering the
cultivation temperature, as for myxopyronin (data not shown). Therefore,
biosynthetic gene clusters of other PKS- and NRPS-derived myxobacterial
products should be cloned into M. xanthus to investigate if the diﬀerences
originate from the diﬀerences in the biosynthetic machineries or if every prod-
uct has individual production kinetics.
With the product titer improvement to the range of 100-500 mg L-1, the
amounts needed for further drug development stages can be easily reached
(Figure 5.1). Commercial production of e.g. antibiotics however is estimated
to reach 20-50 g L-1 [253]. These numbers make clear that the improvements
made in this thesis can only be the ﬁrst steps towards the introduction of
myxobacterial compounds as marketable drugs. Besides the bioprocess en-
gineering, especially mutagenesis and metabolic engineering approaches (as
described in chapter 1.6.3) need to be employed to improve the yield further
[254].
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